var title_f22_17_22800="RML RLL atelectasis-II";
var content_f22_17_22800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frontal chest radiograph reveals combined right middle and right lower lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The interface formed by the minor fissure with the right upper lobe mimics an elevated right hemidiaphragm (arrow). The descending right pulmonary artery, right heart border and the right hemidiaphragm are engulfed by the atelectasis and are obscured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22800=[""].join("\n");
var outline_f22_17_22800=null;
var title_f22_17_22801="Treponema pallidum silver stain";
var content_f22_17_22801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Treponema pallidum, silver stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spirochetes of",
"    <em>",
"     Treponema pallidum",
"    </em>",
"    , visualized by silver impregnation, in the eye of a child with congenital syphilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed. Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22801=[""].join("\n");
var outline_f22_17_22801=null;
var title_f22_17_22802="Ileostomy PI";
var content_f22_17_22802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Ileostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 672px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows an ileostomy. To make an ileostomy, a doctor makes a small opening in the belly. This opening is called a &ldquo;stoma.&rdquo; Then he or she connects the small intestine to the stoma. Bowel movements exit the body through the stoma. They go into a bag that is attached to the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22802=[""].join("\n");
var outline_f22_17_22802=null;
var title_f22_17_22803="CLL smear";
var content_f22_17_22803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral blood smear in a patient with chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood smear from a patient with B cell chronic lymphocytic leukemia. The predominant lymphocytes have a very sparse cytoplasm, round to slightly oval nuclei, and no evident nucleoli. Damaged lymphocytes (\"smudge cells\") are present (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22803=[""].join("\n");
var outline_f22_17_22803=null;
var title_f22_17_22804="Calcipotriol (calcipotriene) and betamethasone: Patient drug information";
var content_f22_17_22804=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcipotriol (calcipotriene) and betamethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/49/29462?source=see_link\">",
"     see \"Calcipotriol (calcipotriene) and betamethasone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2524976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Taclonex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dovobet&reg;;",
"     </li>",
"     <li>",
"      Xamiol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to betamethasone, calcipotriene, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a skin infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on the face, groin, armpits, or other skin fold parts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To use on the scalp, part your hair. Put drug on the affected skin. Rub in gently and let it dry. You may wash your hair as normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4044122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wait 12 hours before putting on hair that has been chemically treated.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4044123",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wash hair right after using.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of suspension not used after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11473 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22804=[""].join("\n");
var outline_f22_17_22804=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140722\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014799\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014798\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014803\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014804\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014806\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014801\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014802\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014807\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014808\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/49/29462?source=related_link\">",
"      Calcipotriol (calcipotriene) and betamethasone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_17_22805="Nephrology pattern 1 answer";
var content_f22_17_22805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postinfectious glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power light micrograph showing marked cellular proliferation and neutrophilic infiltration (arrows) within the glomerular tuft in postinfectious glomerulonephritis. Few open capillary lumens can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22805=[""].join("\n");
var outline_f22_17_22805=null;
var title_f22_17_22806="Barretts squamous island";
var content_f22_17_22806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus beneath squamous mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view demonstrates the glandular epithelium of Barrett's esophagus with an island of overlying squamous mucosa (arrows). Larger areas of squamous mucosa may render underlying Barrett's esophagus inapparent on endoscopy. This has been a concern in patients treated by some forms of ablative therapy in which replacement of columnar epithelium by squamous epithelium may not obviate the risk of malignant transformation from underlying Barrett's mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22806=[""].join("\n");
var outline_f22_17_22806=null;
var title_f22_17_22807="Tinea versicolor arm";
var content_f22_17_22807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59533%7EPC%2F78860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59533%7EPC%2F78860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small salmon-colored macules are evident on the arm that coalesce in some areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple light brown coalescing macules are present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22807=[""].join("\n");
var outline_f22_17_22807=null;
var title_f22_17_22808="Acute and early HIV infection: Treatment";
var content_f22_17_22808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute and early HIV infection: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22808/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22808/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22808/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22808/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22808/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/17/22808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first description of acute HIV infection, a \"mononucleosis-like\" illness, based upon the clinical records of 12 men with documented seroconversion to HIV during the preceding six months, was published in 1985 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/1\">",
"     1",
"    </a>",
"    ]. Since then, the early period following acquisition of HIV has been a subject of tremendous clinical and research interest, yet many challenges remain in its diagnosis, management, and impact on public health.",
"   </p>",
"   <p>",
"    Difficulties in identifying patients with early HIV infection have hindered the performance of trials to evaluate the long-term clinical benefits of initiation of antiretroviral therapy during this stage of infection. Thus, decisions for treatment initiation during this period must balance the potential benefits based on indirect evidence, including effects on surrogate markers, and the potential risks of earlier therapy. In addition, the general trend in treatment guidelines in favor of treating all individuals with HIV infection influences the approach in early infection toward treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of early HIV infection will be reviewed here. The pathogenesis, epidemiology, clinical manifestations, and diagnosis of acute and early infection with HIV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link\">",
"     \"Acute and early HIV infection: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14195827\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different terms, including acute, recent, primary, and early HIV infection, have been used in the literature to refer to variable intervals following initial infection with the virus. In this topic, we use the term &ldquo;early HIV infection&rdquo; to refer to the approximate six-month period following HIV acquisition. We use the term &ldquo;acute HIV infection,&rdquo; to refer to symptomatic early infection, as this reflects common usage in clinical care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3821755\">",
"    <span class=\"h1\">",
"     DECISION TO INITIATE ANTIRETROVIRAL THERAPY DURING EARLY HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For chronically infected HIV patients, a growing body of evidence from trials and large observational studies that demonstrate a reduction in AIDS and non-AIDS morbidity and mortality with antiretroviral therapy (ART) across a wide range of CD4 cell counts has led to the recommendation by many experts for ART initiation regardless of CD4 cell count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H5#H5\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Rationale for treatment of all HIV-infected patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, because of difficulties in identifying patients with early infection, there are fewer clear data on the clinical long-term benefits of initiating treatment during this stage of HIV infection. Thus, most of the rationale for initiating treatment in early HIV infection is extrapolated from indirect evidence, theoretical benefits, and effects of ART on surrogate markers of HIV disease progression (ie, CD4 cell count and HIV RNA). The decision to initiate antiretroviral therapy in early infection must balance these potential benefits with the potential risks of ART. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3821762\">",
"    <span class=\"h2\">",
"     Rationale for initiation of ART in early infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14196025\">",
"    <span class=\"h3\">",
"     Effect on symptomatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence and severity of symptoms during early HIV infection appear to portend more rapid disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. As an example, in a study of 218 female sex workers with well-documented dates of HIV seroconversion based on longitudinal screening, each additional symptom present at the time of acute infection was associated with an increasing risk of overall mortality after a median follow-up of 4.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, those with acute symptomatic HIV infection may represent a subset of patients in whom earlier initiation of ART would be more likely to confer improvement in morbidity and mortality that would thus outweigh potential risks.",
"   </p>",
"   <p>",
"    Additionally, because symptoms of acute HIV infection are thought to be related to the high level of circulating virus, either through direct effect or indirectly through the immune response to viral infection, early treatment with ART, through rapid reduction in the HIV RNA level, may be able to attenuate the severity of symptoms. However, there are no clinical data that clearly demonstrate this theoretical effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175057132\">",
"    <span class=\"h3\">",
"     Improved clinical markers of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in chronic infection, ART is effective in suppressing serum viral RNA levels and increasing CD4 cell counts in the vast majority of patients with acute and early HIV infection. As an example, in a prospective longitudinal study of 102 patients infected with HIV within the preceding 12 months who initiated ART, 97 percent achieved undetectable viral levels at a median of 11 weeks, and 66 of 72 patients (92 percent) maintained virologic suppression at 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/6\">",
"     6",
"    </a>",
"    ]. The CD4 cell count increased from a mean nadir of 422",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    to a mean of 702",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Furthermore, initiation of ART earlier after initial HIV infection may be associated with a greater chance of immune reconstitution to normal or near normal CD4 cell levels. In a prospective study of predominantly white men with a well-estimated date of HIV infection, a peak in the CD4 cell count at four months after infection followed by a progressive decline was observed in the absence of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/7\">",
"     7",
"    </a>",
"    ]. Among the 97 patients who initiated ART within that four-month window, the likelihood and rate of CD4 cell count recovery were both greater compared with the 116 patients who initiated ART at a later time (64 versus 34 percent achieved a CD4 cell count &gt;900",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    by 48 months of ART and at a median of 3.8 versus 15.2 months after ART initiation, respectively). CD4 cell count recovery to this threshold was also more likely and rapid in patients who initiated therapy at a baseline CD4 cell count greater than 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    versus less than 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Although patients treated within four months of infection had higher average CD4 cell counts at initiation than those treated later, in multivariate analyses, initiation of ART earlier and at a higher CD4 cell count each remained independent predictors of CD4 cell count recovery.",
"   </p>",
"   <p>",
"    Limitations of this observational study include heterogeneity between the two groups (ie, there were a greater number of non-white patients in the group who initiated ART later), the possibility that those treated earlier may have had other unspecified clinical characteristics that would have impacted CD4 cell count recovery, and the lack of clinical end-points. Nevertheless, the results support the concept that earlier treatment following HIV acquisition is associated with improvements in an important surrogate marker of HIV disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3821770\">",
"    <span class=\"h3\">",
"     Interval until treatment criteria are met is short",
"    </span>",
"    &nbsp;&mdash;&nbsp;With mounting data demonstrating benefits of ART for chronically infected HIV patients at increasingly higher CD4 cell counts, the interval following initial infection until the CD4 cell count declines to a threshold at which there is clinical evidence for a benefit with ART is likewise becoming increasingly short. Data from observational studies and a controlled trial suggest that initiation of ART in chronically infected patients with CD4 cell counts between 350 and 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    decreases AIDS-related events and improves survival [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. There are fewer data for the benefit of ART initiation in patients with CD4 cell counts greater than 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    but results of a large observational study suggest a decreased risk of death with treatment above that CD4 cell count threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/11\">",
"     11",
"    </a>",
"    ]. These data are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H2622983#H2622983\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'The clinical benefit of ART varies by baseline CD4 cell count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The time to reach these CD4 cell count levels following HIV acquisition appears relatively short. In one study of patients acutely infected with HIV, the probability of having a CD4 cell count less than 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    was 0.57, 0.72, 0.79 and 0.84 at baseline, two, four, and six years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/13\">",
"     13",
"    </a>",
"    ]. Similarly, in a large prospective study of patients with well-estimated dates of HIV infection (the Concerted Action on Seroconversion to AIDS and Death in Europe, or CASCADE cohort), the estimated median time from infection to CD4 cell count decline to &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    was 1.19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/14\">",
"     14",
"    </a>",
"    ]. Even if lower CD4 cell count thresholds are used, the time to meeting them may also be relatively short. As an example, one trial evaluating treatment of patients with early HIV infection was halted prematurely because a considerable proportion of the 40 patients randomly assigned to delay ART until prespecified treatment criteria (including a CD4 cell count &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    were met required ART initiation within the trial period (28 and 50 percent at 36 and 72 weeks, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, patients with early HIV who start therapy would likely not have a significant excess of ART exposure compared with deferring therapy until CD4 cell counts decline to a level at which ART has been demonstrated to provide clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3821945\">",
"    <span class=\"h3\">",
"     Decreased risk of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early HIV infection is associated with high levels of HIV RNA and a corresponding high risk of viral transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Although the estimated contribution of early HIV infection to new infections within a community differs by population studied and model used, in some cases, up to 50 percent of new infections are thought to be transmitted from acutely infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/16,18-22\">",
"     16,18-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link&amp;anchor=H20#H20\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\", section on 'Infectivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No clinical trials have directly assessed the effect of treatment of early HIV infection on subsequent transmission rates. However, data from studies of chronically infected patients suggest that reduction of viral load through effective ART substantially reduces transmission to uninfected sexual partners [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/12\">",
"     12",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    ). It is reasonable to assume that a reduction in transmission risk would similarly occur with lowering and suppressing viral RNA level through ART in patients with early HIV infection. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3821938\">",
"    <span class=\"h3\">",
"     Improved markers of immune cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several in vitro studies have suggested that ART initiated early during HIV infection can lead to improvements in the ability of immune cells to control the virus. As an example, initiation of ART during acute infection appears to preserve HIV-specific T cell function that would otherwise deteriorate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Markers of B cell dysfunction and apoptosis that are seen in chronic infection appear during early HIV infection and can also be reversed with early ART initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/25\">",
"     25",
"    </a>",
"    ]. Other studies have suggested that ART in early infection leads to more rapid declines in cellular viral reservoirs compared with treatment in chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether these changes in markers of immune function translate into clinical benefits is as yet unclear. Nevertheless, these observations initially fueled interest in whether early ART can alter the natural history of HIV disease such that ART may not have to be continued indefinitely. Studies evaluating this theory are discussed in detail below. Of note, treatment interruption strategies are not recommended at any stage of HIV infection; hence these studies are summarized primarily because of the lessons learned about this distinctive population with recently acquired HIV. (See",
"    <a class=\"local\" href=\"#H77550952\">",
"     'Can brief ART in early infection alter disease course?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822097\">",
"    <span class=\"h2\">",
"     Potential risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of early treatment must be balanced against the possible risks of ART.",
"    <br/>",
"   </p>",
"   <p>",
"    One concern for initiating ART during early infection, when the rate of viral replication is particularly rapid, is that suboptimal adherence could more readily lead to the evolution of drug resistance mutations. However, there is no clinical evidence that resistance is more likely to occur in patients treated during early HIV infection than with long-established disease. Nevertheless, commitment to strict adherence if treatment is initiated at this time is important.",
"   </p>",
"   <p>",
"    Additionally, although current antiretroviral options have more favorable side effect profiles than their predecessors, concerns about toxicities with the long-term use of ART remain, including the metabolic risks of protease inhibitors and the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    on bone density. However, whether delaying ART until criteria for treatment in chronic infection are met would attenuate these risks is unknown. Furthermore, the current trend towards initiating ART at higher CD4 cell counts minimizes the amount of ART exposure that a patient would be spared by deferring treatment until those criteria are met, as above. (See",
"    <a class=\"local\" href=\"#H3821770\">",
"     'Interval until treatment criteria are met is short'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77550810\">",
"    <span class=\"h2\">",
"     Recommendations from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the Department of Health and Human Services (DHHS) guidelines on the treatment of HIV recommend initiation of ART for all HIV-infected patients, including those with early HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/2\">",
"     2",
"    </a>",
"    ]. Initiation of ART is specifically recommended for pregnant women with early HIV infection, in order to reduce the risk of transmission to the infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment guidelines from the International-AIDS Society-USA recommend ART for patients with acute symptomatic HIV infection to prevent rapid progression and preserve immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/28\">",
"     28",
"    </a>",
"    ]. Although these guidelines acknowledge the potential benefits for initiating ART in the setting of early HIV and note that offering treatment to acutely infected patients is a high priority for prevention strategies, they do not specifically make recommendations for ART in asymptomatic patients with early HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77550817\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with patients with established HIV, we offer all patients with acute or early HIV infection antiretroviral therapy because the potential benefits to the individual and to public health outweigh the possible drawbacks of earlier ART. Those with acute symptomatic infection, in particular, may be at greatest risk of delaying therapy given the association between symptomatic disease and more rapid progression, and our recommendation to start therapy is thus stronger for this group.",
"   </p>",
"   <p>",
"    Since there is no controlled clinical trial comparing immediate versus deferred continual therapy in patients with early HIV, for individuals who are not committed to taking therapy or who have significant barriers to adherence, a strategy of monitoring without HIV treatment is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF EARLY HIV INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175057212\">",
"    <span class=\"h2\">",
"     Patients who initiate antiretroviral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84364659\">",
"    <span class=\"h3\">",
"     Treatment setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a diagnosis of acute or early HIV infection is made, patients should ideally be referred to a provider with experience in HIV management. We also offer all patients with early HIV the opportunity to participate in clinical studies exploring the pathogenesis of HIV disease and its immunologic response. Listings of available trials can be found at",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84364674\">",
"    <span class=\"h3\">",
"     Choice and initiation of antiretroviral regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the decision is made to treat a patient with acute or early HIV infection, the ultimate choice of antiretroviral regimen should be guided by the results of drug resistance testing, as transmission of virus harboring at least one resistance mutation has been reported in up to 20 percent of patients with early HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link\">",
"     \"Acute and early HIV infection: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link&amp;anchor=H13#H13\">",
"     \"Drug resistance testing in the clinical management of HIV infection\", section on 'Interpretation of resistance testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, treatment should optimally not be delayed while awaiting results of resistance testing in the setting of acute or early HIV infection. In such cases, a regimen that contains a boosted protease inhibitor may be preferable to a regimen that contains a non-nucleoside reverse transcriptase inhibitor, as resistance to the latter is more common [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/2\">",
"     2",
"    </a>",
"    ]. Additionally, a regimen containing a boosted protease inhibitor may retain efficacy despite the presence of certain common resistance mutations. In a study of 109 patients with primary HIV infection, the 13 patients infected with virus that harbored minority variant resistance mutations (including the M184V mutation that confers resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ) all achieved virological suppression on a protease inhibitor-based regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/32\">",
"     32",
"    </a>",
"    ]. Once the results of resistance testing are available, treatment modifications can be made accordingly.",
"   </p>",
"   <p>",
"    In the event that a patient is infected with wild-type virus, we agree with the United States Department of Health and Human Services recommendations to initiate one of the first-line regimens recommended for chronic HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/2\">",
"     2",
"    </a>",
"    ]. There are no clinical trials that have compared the efficacy of various antiretroviral therapy (ART) regimens in patients with early HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H36#H36\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Selecting a regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101944727\">",
"    <span class=\"h3\">",
"     Monitoring during antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initiation of ART during early HIV infection, viral RNA levels should be checked regularly to document and ensure viral suppression. This can be done at intervals recommended for patients starting ART during chronic infection, as time to viral suppression on ART is comparable in early and chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link&amp;anchor=H9#H9\">",
"     \"Patient monitoring during HIV antiretroviral therapy\", section on 'Frequency of laboratory monitoring'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Routine monitoring of other laboratory tests and for side effects is also similar to that recommended for chronic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link&amp;anchor=H9#H9\">",
"     \"Patient monitoring during HIV antiretroviral therapy\", section on 'Frequency of laboratory monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once treatment is initiated, ART is continued indefinitely.",
"   </p>",
"   <p>",
"    Although many studies have attempted to evaluate the benefit of a discrete course of ART initiated during acute or early infection followed by treatment interruption, results from these studies have been mixed and there is no clear evidence of long-term benefit of such an approach (see",
"    <a class=\"local\" href=\"#H77550952\">",
"     'Can brief ART in early infection alter disease course?'",
"    </a>",
"    below). In contrast, controlled trials have demonstrated that treatment interruption following initiation of ART during chronic infection is strongly associated with an increase in mortality as well as AIDS and non-AIDS morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]; thus treatment interruption is not a recommended strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link&amp;anchor=H3394096#H3394096\">",
"     \"Structured treatment interruptions in the HIV-infected patient\", section on 'Treatment interruption is associated with poor clinical outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the rebound in viral load following treatment interruption may be lower among those who initiated ART during early compared with chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/35\">",
"     35",
"    </a>",
"    ], there is no evidence that treatment interruptions are thus safer in this setting. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175057262\">",
"    <span class=\"h2\">",
"     Patients who defer antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although we generally favor earlier initiation of ART for patients with early HIV infection, some patients will opt to defer ART or otherwise not be ready to commit to lifelong ART. If a decision is made to defer therapy, we perform close clinical and laboratory (CD4 cell count and viral load testing) monitoring (ie, every three months) for evidence of rapid immunologic decline, which would indicate a greater urgency for initiation of ART to prevent poor clinical outcomes. Additionally, patients should be counselled on the high risk of transmission in the setting of primary HIV infection, when viral RNA levels are typically very high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77550952\">",
"    <span class=\"h1\">",
"     CAN BRIEF ART IN EARLY INFECTION ALTER DISEASE COURSE?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has long been interest in whether a discrete course of antiretroviral therapy (ART) started in the earliest stages of infection could alter the natural progression of the disease, decreasing the viral load set point, increasing the time to CD4 cell count decline, and thus delaying the time to reinitiate ART for clinical indications. However, it has been difficult to identify and enroll patients in studies to evaluate this hypothesis, and results from the few controlled trials that have been performed are mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/15,36-38\">",
"     15,36-38",
"    </a>",
"    ]. Even in those trials that demonstrate a benefit to short-term ART in the acute setting with regards to HIV disease parameters, the duration and clinical significance of these benefits are unclear. Results from observational studies are similarly mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. Thus, given the substantial evidence from clinical trials of poor clinical outcomes associated with treatment interruption in the setting of chronic HIV infection, we do not recommend a temporary course of early ART for acutely infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link&amp;anchor=H3394096#H3394096\">",
"     \"Structured treatment interruptions in the HIV-infected patient\", section on 'Treatment interruption is associated with poor clinical outcomes'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The range of findings from trials evaluating the effects of short-term ART in the setting of early HIV infection is illustrated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-label trial (Primo-SHM) of 115 patients with HIV seroconversion within the preceding six months, patients randomly assigned to receive an early, discrete course of ART experienced modest improvements in clinical markers of disease following treatment interruption compared with patients whose ART was delayed until clinically indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/36\">",
"       36",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Similar findings were reported from an international trial (Short Pulse Anti-Retroviral Therapy at Seroconversion, or SPARTAC) of 366 patients with HIV seroconversion within the preceding six months who were randomly assigned to receive 12 weeks of ART, 48 weeks of ART, or no ART [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/45\">",
"       45",
"      </a>",
"      ]. The primary endpoint was a CD4 cell count decline &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or other indication for long-term ART initiation, and patients were followed for a mean of 4.2 years. Patients who received an early, temporary ART regimen for 48 weeks had a longer time following treatment interruption to reach the primary endpoint (median 222 weeks) compared with those who received 12 weeks of ART (median 184 weeks) and those who did not receive ART in the setting of early infection (median 157 weeks following randomization to meeting criteria for long-term ART). In a post-hoc analysis, there was a nonsignificant trend towards a longer time to CD4 cell count decline among patients who initiated the 48-week ART course earlier following seroconversion. Additionally, the mean decrease in viral RNA level from baseline was greater in patients who received 48 weeks of ART compared with those who received no ART when measured at 36 weeks following treatment interruption or randomization, respectively (difference -0.44 log",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      There were no differences between the three groups in AIDS diagnoses or death within the limited follow-up period.",
"     </li>",
"     <li>",
"      In a separate trial (AIDS Clinical Trial Group A5217), 130 patients who were infected with HIV within the preceding six months but had already developed a positive Western blot were randomly assigned to receive 36 weeks of immediate ART followed by treatment discontinuation or to delay ART until prespecified treatment criteria were met (including CD4 cell count &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      consecutively over at least four weeks or &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      at any time) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22808/abstract/15\">",
"       15",
"      </a>",
"      ]. The primary objective of the trial was to assess the effect of early ART on viral RNA levels once off treatment. However, the study was discontinued prematurely because of a high rate of progression to treatment requirement in the delayed ART arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The aggregate message from these controlled trials is that a course of early therapy does provide some benefits in surrogate markers of HIV disease (ie, the CD4 cell count and HIV RNA). However, since treatment interruption is no longer a recommended strategy in HIV disease management, the practical importance of these studies for clinical management is limited. They are summarized here primarily because of the lessons learned about this distinctive population with recently acquired HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651176\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In this topic, we use the term &ldquo;early HIV infection&rdquo; to refer to the approximate six-month period following HIV acquisition. We use the term &ldquo;acute HIV infection,&rdquo; to refer to symptomatic early infection. (See",
"      <a class=\"local\" href=\"#H14195827\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of difficulties in identifying patients with early HIV infection for enrollment in controlled trials, most of the rationale for initiating antiretroviral treatment (ART) in early HIV infection is based on indirect evidence from chronic infection, theoretical benefits to the individual and public health, and the effects of ART during early infection on surrogate markers of HIV disease progression (ie, CD4 cell count and HIV RNA). (See",
"      <a class=\"local\" href=\"#H3821755\">",
"       'Decision to initiate antiretroviral therapy during early HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence and severity of symptoms during early HIV infection appear to portend more rapid disease progression. Thus, those with acute symptomatic HIV infection may represent a subset of patients in whom earlier initiation of ART would be more likely to confer improvement in morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H14196025\">",
"       'Effect on symptomatic disease'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      As in chronic infection, ART is effective in suppressing serum viral RNA levels and increasing CD4 cell counts in the vast majority of patients with acute and early HIV infection. Furthermore, initiation of ART earlier after initial HIV infection may be associated with a greater chance of immune reconstitution to normal or near normal CD4 cell levels. (See",
"      <a class=\"local\" href=\"#H175057132\">",
"       'Improved clinical markers of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The interval following initial infection until the CD4 cell count declines to a threshold at which there is clinical evidence for a benefit with ART is relatively short. Thus, patients with early HIV who start therapy would likely not have a significant excess of ART exposure compared with deferring therapy. This may ameliorate concerns about the possible risk of additional toxicity from greater time on ART. (See",
"      <a class=\"local\" href=\"#H3821770\">",
"       'Interval until treatment criteria are met is short'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3822097\">",
"       'Potential risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early HIV infection is associated with high levels of HIV RNA and a corresponding high risk of viral transmission. Reduction of this transmission risk through viral suppression is a theoretical but plausible benefit to earlier ART initiation. (See",
"      <a class=\"local\" href=\"#H3821945\">",
"       'Decreased risk of transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall, these potential benefits of earlier ART outweigh the potential risks of increased exposure to the toxicity of ART and emergence of viral resistance in the setting of suboptimal adherence. (See",
"      <a class=\"local\" href=\"#H77550817\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with acute symptomatic HIV infection, we suggest initiation of ART (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Given the association between symptomatic disease and more rapid disease progression, these patients may be at greatest risk of delaying therapy and thus we feel strongly about treatment initiation in such patients.",
"     </li>",
"     <li>",
"      For patients with asymptomatic early HIV infection who are committed to lifelong therapy, we also suggest initiation of ART (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For those asymptomatic individuals who are not committed to taking therapy or who have significant barriers to adherence, a strategy of monitoring without HIV treatment is reasonable. We perform clinical evaluation, CD4 cell count, and viral load testing every three months for evidence of rapid immunologic decline, which would indicate a greater urgency for initiation of ART to prevent poor clinical outcomes. (See",
"      <a class=\"local\" href=\"#H175057262\">",
"       'Patients who defer antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ultimate choice of antiretroviral regimen should be guided by the results of drug resistance testing, as transmission of virus harboring at least one resistance mutation is not uncommon. However, treatment does not have to be delayed while awaiting results of resistance testing. &nbsp;While awaiting results of resistance testing, we suggest an initial regimen that includes a protease inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Once initiated, ART is continued indefinitely. (See",
"      <a class=\"local\" href=\"#H84364674\">",
"       'Choice and initiation of antiretroviral regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Duration of treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trials evaluating the effects of a discrete course of ART early in HIV infection suggest an improvement in surrogate markers of HIV disease with earlier versus delayed therapy, but the durability of these benefits following ART discontinuation is unclear. In contrast, substantial evidence from clinical trials in chronic infection demonstrate increased AIDS and non-AIDS related morbidity and mortality with treatment discontinuation. Thus, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      using a treatment interruption strategy in patients with acute or early HIV infection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H77550952\">",
"       'Can brief ART in early infection alter disease course?'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link\">",
"       \"Structured treatment interruptions in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/1\">",
"      Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985; 1:537.",
"     </a>",
"    </li>",
"    <li>",
"     Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. file://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. (Accessed on February 13, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/3\">",
"      Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008; 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/4\">",
"      Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/5\">",
"      Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/6\">",
"      Kassutto S, Maghsoudi K, Johnston MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006; 42:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/7\">",
"      Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/8\">",
"      Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/9\">",
"      HIV-CAUSAL Collaboration, Ray M, Logan R, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/10\">",
"      Sabine C, Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/11\">",
"      Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/12\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/13\">",
"      Minga AK, Lewden C, Gabillard D, et al. CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters. AIDS 2011; 25:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/14\">",
"      Lodi S, Phillips A, Touloumi G, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds &lt;200, &lt;350, and &lt;500 Cells/mm&sup3;: assessment of need following changes in treatment guidelines. Clin Infect Dis 2011; 53:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/15\">",
"      Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012; 205:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/16\">",
"      Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/17\">",
"      Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/18\">",
"      Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/19\">",
"      Xiridou M, Geskus R, de Wit J, et al. Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS 2004; 18:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/20\">",
"      Abu-Raddad LJ, Longini IM Jr. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 2008; 22:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/21\">",
"      Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/22\">",
"      O'Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep 2012; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/23\">",
"      Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/24\">",
"      Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A 2000; 97:3382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/25\">",
"      Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005; 19:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/26\">",
"      Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/27\">",
"      Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/28\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/29\">",
"      Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/30\">",
"      Jain V, Liegler T, Vittinghoff E, et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010; 5:e15510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/31\">",
"      Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/32\">",
"      Metzner KJ, Rauch P, von Wyl V, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010; 201:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/33\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/34\">",
"      Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/35\">",
"      Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012; 7:e43754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/36\">",
"      Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med 2012; 9:e1001196.",
"     </a>",
"    </li>",
"    <li>",
"     Fidler S and the SPARTAC Trials investigators. The effect of short-course antiretroviral therapy in primary HIV infection: final results from an international randomised controlled trial; SPARTAC. Presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Rome, Italy, July 17-20, 2011, #WELBX06",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/38\">",
"      Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012; 26:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/39\">",
"      Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/40\">",
"      Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/41\">",
"      Seng R, Goujard C, Desquilbet L, et al. Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 2008; 49:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/42\">",
"      Pantazis N, Touloumi G, Vanhems P, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008; 22:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/43\">",
"      Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/44\">",
"      Hoen B, Fournier I, Lacabaratz C, et al. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 2005; 40:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22808/abstract/45\">",
"      SPARTAC Trial Investigators, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013; 368:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3717 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A18C3F2596-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22808=[""].join("\n");
var outline_f22_17_22808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H651176\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14195827\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3821755\">",
"      DECISION TO INITIATE ANTIRETROVIRAL THERAPY DURING EARLY HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3821762\">",
"      Rationale for initiation of ART in early infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14196025\">",
"      - Effect on symptomatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175057132\">",
"      - Improved clinical markers of disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3821770\">",
"      - Interval until treatment criteria are met is short",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3821945\">",
"      - Decreased risk of transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3821938\">",
"      - Improved markers of immune cell function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822097\">",
"      Potential risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77550810\">",
"      Recommendations from expert groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77550817\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT OF EARLY HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175057212\">",
"      Patients who initiate antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84364659\">",
"      - Treatment setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84364674\">",
"      - Choice and initiation of antiretroviral regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101944727\">",
"      - Monitoring during antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175057262\">",
"      Patients who defer antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77550952\">",
"      CAN BRIEF ART IN EARLY INFECTION ALTER DISEASE COURSE?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651176\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=related_link\">",
"      Acute and early HIV infection: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_17_22809="Viral meningitis: Epidemiology, pathogenesis, and etiology in children";
var content_f22_17_22809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Viral meningitis: Epidemiology, pathogenesis, and etiology in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22809/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22809/contributors\">",
"     Cecilia Di Pentima, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22809/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22809/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22809/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22809/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/17/22809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral meningitis is defined as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A febrile illness with clinical signs and symptoms of meningeal irritation",
"     </li>",
"     <li>",
"      No associated neurologic dysfunction",
"     </li>",
"     <li>",
"      No evidence of bacterial pathogens in the cerebrospinal fluid (CSF) in a patient who has not received prior antibiotics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and etiology of viral meningitis will be reviewed here. Clinical manifestations, diagnosis, treatment, and prevention of viral meningitis and bacterial meningitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=see_link\">",
"     \"Viral meningitis: Management, prognosis, and prevention in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral meningitis accounts for approximately 26,000 to 42,000 hospitalizations each year in the United States, affecting mainly infants younger than one year and children 5 to 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The highest incidence of aseptic meningitis in the United States occurs from late spring to the autumn months, reflecting the peak activity of enteroviral and arthropod-borne infections (",
"    <a class=\"graphic graphic_table graphicRef59663 \" href=\"UTD.htm?13/27/13757\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most viral pathogens affecting the CNS initially infect mucosal surfaces of the respiratory and gastrointestinal tract, followed by viral replication in regional lymph nodes. This precedes a primary viremia that signals the onset of illness and subsequent seeding of other organs. Except for neonatal HSV infection, most viruses reach the CNS during a second viremia that follows viral replication in other organs, particularly the liver and spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms involved in viral transport from the circulation to the brain are not clearly understood. However, it is clear that transendothelial passage of the virus occurs in vessels of the choroid plexus, meninges, or cerebrum by one or more of the following mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bridging the endothelium within migrating leukocytes",
"     </li>",
"     <li>",
"      Pinocytosis or colloidal transport",
"     </li>",
"     <li>",
"      Breaking through damaged endothelium",
"     </li>",
"     <li>",
"      Direct infection of endothelial cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of viral meningitis associated with specific viruses is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroviruses are the most common cause of viral meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/1\">",
"     1",
"    </a>",
"    ]. Other important causes of viral meningitis in children include human parechoviruses, herpesviruses, arboviruses, lymphocytic choriomeningitis virus, rabies, and influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Enteroviruses",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiology &ndash; Enteroviruses (EV) are responsible for 85 to 95 percent of cases of viral meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/1\">",
"       1",
"      </a>",
"      ]. Nonpolio-EV serotypes cycle from year to year; however, certain serotypes have remained prevalent. Coxsackieviruses A9, B5, and B1 and echoviruses 6, 9, 13, 18, and 30 were the most common serotypes isolated in the United States from 2000 to 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/4\">",
"       4",
"      </a>",
"      ]. Aseptic meningitis in infants under three months of age has been associated mainly with group B coxsackieviruses and parechoviruses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. The epidemiology of enterovirus infection is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=see_link&amp;anchor=H5#H5\">",
"       \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\", section on 'Epidemiology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      EV 71, closely related to coxsackievirus A16 and the viral agent of hand-foot-mouth disease, has emerged as a significant cause of aseptic meningitis, encephalitis, and myelitis. It has been responsible for major outbreaks in Asia and sporadic cases in the United States and Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/8-12\">",
"       8-12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=see_link&amp;anchor=H7#H7\">",
"       \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\", section on 'Serotypes and disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Approximately 1 percent of wild poliovirus infections are associated with paralytic illness. More common clinical presentations in susceptible individuals are asymptomatic infections, minor illness or abortive poliomyelitis, and aseptic meningitis or nonparalytic poliomyelitis. With successful vaccine eradication campaigns, polioviruses are no longer recovered from patients with aseptic meningitis in developed countries, and only rarely in developing countries where poliomyelitis still occurs. Vaccine strains from the oral polio vaccine have rarely been recovered from the CSF of patients with aseptic meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=see_link\">",
"       \"Polio and infectious diseases of the anterior horn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transmission &ndash; Humans are the only known reservoir for Enteroviruses (EV), and transmission of EV occurs most commonly by the fecal-oral route. A few members of the EV can be acquired by inhalation of infected droplets. Transplacental transmission resulting in stillbirth, abortion, or neonatal infection has been described with many different EV, including polioviruses, coxsackieviruses, and enterovirus 71 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seasonality, risk factors, and incubation &ndash; In temperate climates, most enterovirus (EV) infections occur in outbreaks during the warmest months; however, sporadic cases can develop throughout the year. In the United States, infections are seen more frequently from June to October [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/4\">",
"       4",
"      </a>",
"      ]. In tropical and subtropical regions, the incidence of EV infections remains stable throughout the year. Individual host factors, such as immunodeficiency and age, can predispose to more severe nonpolio EV infections. Furthermore, children with a deficient humoral immunodeficiency, especially X-linked agammaglobulinemia, are at risk for developing chronic meningoencephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/18\">",
"       18",
"      </a>",
"      ]. The incubation period for EV infection is approximately three to six days.",
"     </li>",
"     <li>",
"      Pathogenesis &ndash; The pathogenesis of enterovirus (EV) infections has been extensively studied; however, many questions remain unsolved [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"       19",
"      </a>",
"      ]. Following exposure, viral particles bind to specific receptors on enterocytes and traverse the intestinal lining cells to reach the Peyer's patches in the lamina propia, where they replicate [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"       19",
"      </a>",
"      ]. Few viral particles may replicate in the nasopharynx with subsequent spread to the respiratory tract lymphatics. An initial viremia spreads the virus to other organs, such as liver, spleen, and heart where further replication occurs generating a second major viremia that is associated with signs and symptoms of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"       19",
"      </a>",
"      ]. Seeding of the CNS can occur during the first or second viremia; however, the mechanisms by which the virus enters the CNS remain unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"       19",
"      </a>",
"      ]. An alternative path involving neural spread has been proposed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. The molecular determinants of neurotropism and neurovirulence have been extensively studied for polioviruses and are now under investigation for nonpolio EVs. Genomic differences among EV serotypes might explain the tendency of some strains to cause aseptic meningitis and encephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Human parechoviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parechovirus is a genus of the Picornaviridae virus family. Human parechoviruses include eight serotypes (HPeV types 1 through 8), and several provisional serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. HPeV1 and HPeV2 were formerly classified as echovirus 22 and 23, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/23\">",
"     23",
"    </a>",
"    ]. Symptoms of CNS involvement, including neonatal sepsis, meningitis, encephalitis, and paralysis have been reported with HPeV types 1 and 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/21,24-31\">",
"     21,24-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HPeV have been identified in Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/32-34\">",
"     32-34",
"    </a>",
"    ], Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/7,35-37\">",
"     7,35-37",
"    </a>",
"    ], North America [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/23,30,38\">",
"     23,30,38",
"    </a>",
"    ], and South America [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/39\">",
"     39",
"    </a>",
"    ]. The rate of isolation from the CSF is usually highest between June and October, but varies from region to region and year to year (eg, from 0.4 to 8.2 percent in the Netherlands and 0 to 17 percent in the US) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/7,30,31\">",
"     7,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Herpesviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;All members of the Herpesviridae family can cause aseptic meningitis; however, herpes simplex viruses (HSV) are classically associated with neurologic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"     19",
"    </a>",
"    ]. Cytomegalovirus (CMV), varicella-zoster virus (VZV), human herpesvirus (HHV)-6, and Epstein-Barr virus (EBV) infections are only infrequently associated with meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link&amp;anchor=H6#H6\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\", section on 'Meningoencephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Members of the Herpesviridae family share similar features: the virion, roughly spherical and encased by an envelope, measures 15 to 200 nm in diameter and contains a large double-stranded DNA molecule. Primary infection is followed by lifelong infection, with the potential risk for reactivation.",
"   </p>",
"   <p>",
"    Herpesviridae have a worldwide distribution. Humans are the only reservoir for transmission to susceptible individuals. Infections occur worldwide without seasonal prevalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal and central nervous system (CNS) infections are the most devastating infections caused by HSV. The prevalence of HSV infection was 0.2 percent (95% CI 0.1-0.3 percent) among neonates who were evaluated in the emergency department and admitted to a tertiary-care children's hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The postulated mechanisms involved in the spread of HSV-1 to the brain include hematogenous dissemination, direct extension through the cribriform plate from infection of nasopharyngeal mucosa, or via neurogenic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Whether HSV-2 reaches the meninges by neuronal or hematogenous dissemination is under debate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/43\">",
"     43",
"    </a>",
"    ]. Humoral immunity does not prevent recurrent infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HSV-1 &ndash; HSV-1 is primarily transmitted by direct contact; therefore, the incidence of HSV-1 infection is influenced by socioeconomic status, age, and geographic location [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/44\">",
"       44",
"      </a>",
"      ]. In developing countries, 70 to 80 percent of adolescents have serologic evidence of HSV-1 infection, while the age-specific prevalence of HSV-1 is decreasing in developed countries [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. HSV-1 is the most common etiologic agent of sporadic necrotizing encephalitis, representing more than 85 percent of all cases, and is infrequently associated with aseptic meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/43,45,46\">",
"       43,45,46",
"      </a>",
"      ]. Neonatal infections due to HSV-1 account for 25 percent of all cases of neonatal HSV infection, with an overall incidence of HSV infection in newborns ranging from one case in 2000 to 5000 deliveries per year [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H3#H3\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Epidemiology and transmission'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Infections with HSV-2 are acquired mainly by sexual contact; however, increasing proportions of genital infections are due to HSV-1, acquired from orolabial lesions and herpetic whitlow [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/44\">",
"       44",
"      </a>",
"      ]. Aseptic meningitis syndrome is usually caused by HSV-2 primary infection; it occurs mainly in adults but can occur in young children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HSV-2 &ndash; HSV-2 accounts for 75 percent of neonatal infections due to HSV. Infants become colonized with HSV mainly by vertical transmission through the vaginal canal, less frequently by ascending infection or during the postnatal period by horizontal transmission. The rate of perinatal transmission is 30 to 50 percent with maternal primary infection and 3 percent with recurrent infection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"       \"Genital herpes simplex virus infection and pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Clinical symptoms of meningitis have been reported in 36 percent of women and 11 percent of men with primary HSV-2 infection, but only 25 to 33 percent of patients with HSV meningitis ever report a history of genital lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/43,45,49\">",
"       43,45,49",
"      </a>",
"      ]. Furthermore, recurrent meningitis has been reported in 25 percent of adult patients with HSV-2 meningitis and can occur in young children, but rarely in neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/43,46,50-52\">",
"       43,46,50-52",
"      </a>",
"      ]. Neonates, however, can develop recurrent episodes of encephalitis.",
"      <br/>",
"      <br/>",
"      Mollaret meningitis is characterized by recurrent episodes of aseptic meningitis. Using polymerase chain reaction (PCR)-based testing, HSV-2 has been strongly associated with Mollaret meningitis, a form of benign recurrent aseptic meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/1,53,54\">",
"       1,53,54",
"      </a>",
"      ]. An additional few cases have been reported due to HSV-1 and EBV [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/1,55,56\">",
"       1,55,56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the majority of patients, HSV mucosal lesions precede signs and symptoms of meningeal inflammation with a mean interval of one week [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/43\">",
"       43",
"      </a>",
"      ]. In general, neonates with disseminated and localized infections usually develop symptoms earlier than neonates with CNS infections, on average 9 to 11 days and 16 to 17 days, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/57\">",
"       57",
"      </a>",
"      ]. Beyond the neonatal period, the incubation period ranges from 2 days to 12 days, with a mean of four days [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     VZV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , the incidence of varicella-zoster virus (VZV) infection in children has declined substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/58\">",
"     58",
"    </a>",
"    ]. Furthermore, the overall incidence of neurologic complications of VZV infection in healthy children is less than one percent, most frequently cerebral ataxia and encephalitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22278?source=see_link\">",
"     \"Epidemiology of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aseptic meningitis is a rare complication of chickenpox and herpes zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19,59-61\">",
"     19,59-61",
"    </a>",
"    ]. The syndrome known as zoster sine herpete is characterized by the presence of CSF pleocytosis, documented CNS infection with VZV by PCR, and the absence of typical skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     CMV and EBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aseptic meningitis due to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) is also rare; however, aseptic meningitis is the most common neurologic complication seen in patients with primary EBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The prevalence of EBV infection in pediatric patients has a direct correlation with socioeconomic status, with the highest incidence seen in developing countries. In the United States, approximately 50 percent of five-year-old children are seropositive for EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     HHV-6 and HHV-7",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6, the etiologic agent of roseola, or exanthem subitum, is a common cause of febrile seizures in infancy and has been associated with meningitis in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19,64\">",
"     19,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link&amp;anchor=H6#H6\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\", section on 'Meningoencephalitis'",
"    </a>",
"    .) HHV-7, also associated with exanthem subitum and febrile seizures in infancy, can also cause meningitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14201?source=see_link\">",
"     \"Human herpesvirus 7 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Arboviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arboviruses are a heterogeneous group of arthropod-borne RNA viruses responsible for important epidemics of CNS infections worldwide; these infections have been increasing in frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/27\">",
"     27",
"    </a>",
"    ]. Although encephalitis and meningoencephalitis are more commonly recognized as hallmarks of central nervous system (CNS) infection by most of these viruses, aseptic meningitis is an important clinical manifestation of their disease spectrum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Out of the seven taxonomic families of arboviruses, three are more commonly involved in human disease: Flaviviridae, Togaviridae, and Bunyaviridae (",
"    <a class=\"graphic graphic_table graphicRef55340 \" href=\"UTD.htm?35/54/36716\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/67\">",
"     67",
"    </a>",
"    ]. The most important arboviruses endemic in the United States include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      St. Louis encephalitis virus",
"     </li>",
"     <li>",
"      West Nile virus",
"     </li>",
"     <li>",
"      Eastern equine encephalitis virus",
"     </li>",
"     <li>",
"      Western equine encephalitis virus",
"     </li>",
"     <li>",
"      California encephalitis viruses (most often La Crosse virus, but also Jamestown and snowshoe hare viruses)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These infections are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38023?source=see_link\">",
"     \"St. Louis encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=see_link\">",
"     \"Epidemiology and pathogenesis of West Nile virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of arboviral CNS infection is relatively similar for all pathogens. Viruses are inoculated subcutaneously or intravenously during the bite of an infected vector, most commonly mosquitoes (",
"    <a class=\"graphic graphic_table graphicRef55340 \" href=\"UTD.htm?35/54/36716\">",
"     table 2",
"    </a>",
"    ). Replication in the skin or muscle precedes a primary viremia that subsequently spreads the virus to the reticuloendothelial system or to the CNS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arboviruses have a worldwide distribution, with a highest incidence in tropical and developing regions. In the United States, arboviruses constitute most of the cases of aseptic meningitis that are not due to EV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The incubation period for arboviral infections ranges from 1 to 18 days (",
"    <a class=\"graphic graphic_table graphicRef55340 \" href=\"UTD.htm?35/54/36716\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most arboviruses are maintained in nature in a cycle involving a nonhuman primary vertebrate host and a primary arthropod vector that determine their geographic and seasonal distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/70\">",
"     70",
"    </a>",
"    ]. Human infections are seen most frequently at the peak of mosquito and tick activity during summer and fall, or sporadically when the virus is brought into the peridomestic environment by a bridge vector [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/70\">",
"     70",
"    </a>",
"    ]. The geographic distribution of arboviral infections in the United States is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef55340 \" href=\"UTD.htm?35/54/36716\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The age distribution of infection varies according to the virus. St. Louis encephalitis (SLE) virus is the most common arboviral infection causing aseptic meningitis, and aseptic meningitis accounts for 15 percent of all symptomatic cases of SLE virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"     19",
"    </a>",
"    ]. In children, the incidence of aseptic meningitis can be as high as 35 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19\">",
"     19",
"    </a>",
"    ]. SLE virus infection is more commonly seen in children in the upper midwestern United States where SLE is endemic. On the other hand, infections are more commonly seen in adults in eastern central and Atlantic states where infections are sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38023?source=see_link\">",
"     \"St. Louis encephalitis\"",
"    </a>",
"    .) Children are also more susceptible than adults to CNS infections due to Eastern equine encephalitis and Western equine encephalitis viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    West Nile virus (WNV) has emerged as a major public health concern in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. WNV persists in nature as part of an enzoonotic cycle among wild birds, the primary reservoir, and Culex spp., the main mosquito vector. In the United States, as well as in other temperate climates, WNV infections coincide with the maximal mosquito activity. In the United States, outbreaks occur from July to October, with the highest incidence seen in August [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/73\">",
"     73",
"    </a>",
"    ]. WNV has a more severe outcome in older patients. In children, it is rare and usually mild [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. However, during the mosquito season, WNV should be considered in the differential diagnosis of aseptic meningitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=see_link\">",
"     \"Epidemiology and pathogenesis of West Nile virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other viruses",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     LCMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic choriomeningitis virus (LCMV) is an enveloped, single-stranded RNA virus member of the Arenaviridae family. Although in the past this virus was identified as a significant pathogen of viral meningitis, today it is rarely identified in human CNS infections in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rodents, including hamsters, rats, and mice, harbor and shed LCMV in nasal secretions, saliva, urine, semen, milk, and feces. Children living in impoverished conditions are at higher risk of acquiring the infection through ingestion of animal-urine-contaminated food, exposure of open wounds to contaminated dirt, or inhalation of aerosolized virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/1,75\">",
"     1,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transplacental infection with LCMV was first described in the United States in 1992, although initially reported in England in 1955 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/75\">",
"     75",
"    </a>",
"    ]. Transmission to the fetus occurs primarily during maternal viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/75\">",
"     75",
"    </a>",
"    ]. LCMV infections occur most commonly during the winter months, when rodents seek food and shelter in human dwellings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies is an enveloped, bullet-shaped RNA virus that causes fatal central nervous system (CNS) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/59\">",
"     59",
"    </a>",
"    ]. Transmission of rabies from animal to human occurs mainly through direct contact with saliva from a rabid animal onto mucous membranes or into open wounds or by direct inoculation through a bite, followed by local replication and subsequent spread to the CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/76\">",
"     76",
"    </a>",
"    ]. Once the virus enters neuronal cells, it moves by passive neuronal transit, reaching the CNS by retrograde axonal transport. After reaching the CNS, there is a subsequent centrifugal spread back to peripheral sites, including the salivary and submaxillary glands. Following inhalation of viral particles, rabies virus reaches the CNS by direct neuronal transmission through the olfactory tract after initial replication in the olfactory epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all humans bitten by a rabid animal develop infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/76\">",
"     76",
"    </a>",
"    ]. The incubation period is generally 20 to 60 days; however, it can be a short as five to six days and as long as six months to seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/59\">",
"     59",
"    </a>",
"    ]. Travelers to hyperendemic areas, especially children, are at increased risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza A and B viruses have been associated with different neurologic syndromes in children, including aseptic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/19,77\">",
"     19,77",
"    </a>",
"    ]. Influenza viruses are orthomyxoviruses of three antigenic types, A, B, and C. Influenza viruses are subclassified according to two surface antigens, neuraminidase (NA) and hemagglutinin (HA), with shift and drifts accounting for pandemics and outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/59,77\">",
"     59,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In temperate climates, the circulation of influenza viruses has a seasonal variation, with a peak incidence in the United States during the months of January and February. Children younger than five years are at increased risk for influenza A virus infection of the central nervous system (CNS), mainly encephalitis. Although less frequently, influenza B virus can also be associated with CNS infections, mainly in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/59,78,79\">",
"     59,78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Neurologic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of the CNS is a rare complication of influenza virus infection, mainly presenting as encephalitis, rather than aseptic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/77\">",
"     77",
"    </a>",
"    ]. Children younger than five years are at higher risk for the development of neurologic complications independent of the strain involved [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/59\">",
"     59",
"    </a>",
"    ]. Of the 121 children with fatal Fujian influenza A (a drift strain) in the United States in the 2003 to 2004 season, 60 percent were younger than five years (46 percent of these between six and 23 months of age), and a number of these patients had encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/80\">",
"     80",
"    </a>",
"    ]. The pathogenesis of influenza viral infection of the CNS remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Less common viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common viral pathogens associated with aseptic meningitis and their geographic distribution are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef75752 \" href=\"UTD.htm?15/3/15420\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Human metapneumovirus (hMPV) is a common cause of upper and lower respiratory tract infections in children. The ability of hMPV to invade the CNS was demonstrated in an infant with fatal encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/81\">",
"     81",
"    </a>",
"    ]. hMPV has been isolated from respiratory specimens in children with neurologic manifestations, but evidence of hMPV in the CSF is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22809/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/34/28194?source=see_link\">",
"       \"Patient information: Viral meningitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/35/16946?source=see_link\">",
"       \"Patient information: Aseptic meningitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, viral meningitis mainly affects infants younger than one year and children 5 to 10 years of age. In the United States, the peak incidence occurs from late spring to autumn, reflecting the peak activity of enteroviral and arthropod-borne infections (",
"      <a class=\"graphic graphic_table graphicRef59663 \" href=\"UTD.htm?13/27/13757\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most viral pathogens affecting the central nervous system (CNS) initially infect mucosal surfaces of the respiratory and gastrointestinal tract and reach the CNS through viremia following viral replication. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteroviruses are the most common cause of viral meningitis. Other important causes of viral meningitis in children include human parechoviruses, herpesviruses, arboviruses, lymphocytic choriomeningitis virus, rabies, and influenza. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/1\">",
"      Rotbart HA. Viral meningitis. Semin Neurol 2000; 20:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of aseptic meningitis associated with echoviruses 9 and 30 and preliminary surveillance reports on enterovirus activity--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:761.",
"     </a>",
"    </li>",
"    <li>",
"     Cassady K, Gnann JW, Whitley RJ. Viral infections of the central nervous system. In: Therapy of Infectious Diseases, Baddour L, Gorbach S (Eds), WB Saunders, Philadelphia 2003. p.237.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/4\">",
"      Khetsuriani N, Lamonte-Fowlkes A, Oberst S, et al. Enterovirus surveillance--United States, 1970-2005. MMWR Surveill Summ 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/5\">",
"      Kaplan MH, Klein SW, McPhee J, Harper RG. Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev Infect Dis 1983; 5:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/6\">",
"      Khetsuriani N, Lamonte A, Oberste MS, Pallansch M. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983-2003. Pediatr Infect Dis J 2006; 25:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/7\">",
"      Wolthers KC, Benschop KS, Schinkel J, et al. Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis 2008; 47:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/8\">",
"      Li CC, Yang MY, Chen RF, et al. Clinical manifestations and laboratory assessment in an enterovirus 71 outbreak in southern Taiwan. Scand J Infect Dis 2002; 34:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/9\">",
"      Herrero LJ, Lee CS, Hurrelbrink RJ, et al. Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997-2000. Arch Virol 2003; 148:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/10\">",
"      Kehle J, Roth B, Metzger C, et al. Molecular characterization of an Enterovirus 71 causing neurological disease in Germany. J Neurovirol 2003; 9:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/11\">",
"      Alexander JP Jr, Baden L, Pallansch MA, Anderson LJ. Enterovirus 71 infections and neurologic disease--United States, 1977-1991. J Infect Dis 1994; 169:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/12\">",
"      P&eacute;rez-V&eacute;lez CM, Anderson MS, Robinson CC, et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis 2007; 45:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/13\">",
"      Gutierrez K, Abzug MJ. Vaccine-associated poliovirus meningitis in children with ventriculoperitoneal shunts. J Pediatr 1990; 117:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Acute flaccid paralysis associated with circulating vaccine-derived poliovirus--Philippines, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/15\">",
"      Inaba H, Hori H, Ito M, et al. Polio vaccine virus-associated meningoencephalitis in an infant with transient hypogammaglobulinemia. Scand J Infect Dis 2001; 33:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/16\">",
"      Chow KC, Lee CC, Lin TY, et al. Congenital enterovirus 71 infection: a case study with virology and immunohistochemistry. Clin Infect Dis 2000; 31:509.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry, JD, Krogstad, P. Enterovirus and parechovirus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.756.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/18\">",
"      Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev Biol (Basel) 2001; 105:75.",
"     </a>",
"    </li>",
"    <li>",
"     Rotbart HA. Viral meningitis and the aseptic meningitis syndrome. In: Infections of the Central Nervous System, 2nd ed, Scheld MW, Durack WR (Eds), Lippincott Raven, Philadelphia 1997. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/20\">",
"      Wyatt HV. Provocation poliomyelitis and entry of poliovirus to the CNS. Med Hypotheses 1976; 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/21\">",
"      Levorson RE, Jantausch BA. Human parechoviruses. Pediatr Infect Dis J 2009; 28:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/22\">",
"      Calvert J, Chieochansin T, Benschop KS, et al. Recombination dynamics of human parechoviruses: investigation of type-specific differences in frequency and epidemiological correlates. J Gen Virol 2010; 91:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Nonpolio enterovirus and human parechovirus surveillance --- United States, 2006-2008. MMWR Morb Mortal Wkly Rep 2010; 59:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/24\">",
"      Boivin G, Abed Y, Boucher FD. Human parechovirus 3 and neonatal infections. Emerg Infect Dis 2005; 11:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/25\">",
"      Benschop KS, Schinkel J, Minnaar RP, et al. Human parechovirus infections in Dutch children and the association between serotype and disease severity. Clin Infect Dis 2006; 42:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/26\">",
"      Figueroa JP, Ashley D, King D, Hull B. An outbreak of acute flaccid paralysis in Jamaica associated with echovirus type 22. J Med Virol 1989; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/27\">",
"      Gubler DJ. The global resurgence of arboviral diseases. Trans R Soc Trop Med Hyg 1996; 90:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/28\">",
"      Verboon-Maciolek MA, Groenendaal F, Hahn CD, et al. Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol 2008; 64:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/29\">",
"      Levorson RE, Jantausch BA, Wiedermann BL, et al. Human parechovirus-3 infection: emerging pathogen in neonatal sepsis. Pediatr Infect Dis J 2009; 28:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/30\">",
"      Selvarangan R, Nzabi M, Selvaraju SB, et al. Human parechovirus 3 causing sepsis-like illness in children from midwestern United States. Pediatr Infect Dis J 2011; 30:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/31\">",
"      Sharp J, Harrison CJ, Puckett K, et al. Characteristics of Young Infants in Whom Human Parechovirus, Enterovirus or Neither Were Detected in Cerebrospinal Fluid during Sepsis Evaluations. Pediatr Infect Dis J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/32\">",
"      Ito M, Yamashita T, Tsuzuki H, et al. Isolation and identification of a novel human parechovirus. J Gen Virol 2004; 85:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/33\">",
"      Watanabe K, Oie M, Higuchi M, et al. Isolation and characterization of novel human parechovirus from clinical samples. Emerg Infect Dis 2007; 13:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/34\">",
"      Pham NT, Trinh QD, Khamrin P, et al. Diversity of human parechoviruses isolated from stool samples collected from Thai children with acute gastroenteritis. J Clin Microbiol 2010; 48:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/35\">",
"      Harvala H, Robertson I, Chieochansin T, et al. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. J Infect Dis 2009; 199:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/36\">",
"      Pi&ntilde;eiro L, Vicente D, Montes M, et al. Human parechoviruses in infants with systemic infection. J Med Virol 2010; 82:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/37\">",
"      van der Sanden S, de Bruin E, Vennema H, et al. Prevalence of human parechovirus in the Netherlands in 2000 to 2007. J Clin Microbiol 2008; 46:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/38\">",
"      Abed Y, Boivin G. Human parechovirus types 1, 2 and 3 infections in Canada. Emerg Infect Dis 2006; 12:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/39\">",
"      Drexler JF, Grywna K, St&ouml;cker A, et al. Novel human parechovirus from Brazil. Emerg Infect Dis 2009; 15:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/40\">",
"      Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. J Pediatr 2008; 153:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/41\">",
"      Davis LE, Johnson RT. An explanation for the localization of herpes simplex encephalitis? Ann Neurol 1979; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/42\">",
"      Johnson RT, Mims CA. Pathogenesis of viral infections of the nervous system. N Engl J Med 1968; 278:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/43\">",
"      Bergstr&ouml;m T, Vahlne A, Alestig K, et al. Primary and recurrent herpes simplex virus type 2-induced meningitis. J Infect Dis 1990; 162:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/44\">",
"      Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/45\">",
"      Simko JP, Caliendo AM, Hogle K, Versalovic J. Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to herpes simplex virus (HSV) documented by detection of HSV DNA. Clin Infect Dis 2002; 35:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/46\">",
"      Dupuis C, Despert V, Vigneron P. [Herpetic meningitis in the child]. Arch Pediatr 2002; 9:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/47\">",
"      Do AN, Green PA, Demmler GJ. Herpes simplex virus type 2 meningitis and associated genital lesions in a three-year-old child. Pediatr Infect Dis J 1994; 13:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/48\">",
"      Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991; 324:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/49\">",
"      Schlesinger Y, Tebas P, Gaudreault-Keener M, et al. Herpes simplex virus type 2 meningitis in the absence of genital lesions: improved recognition with use of the polymerase chain reaction. Clin Infect Dis 1995; 20:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/50\">",
"      Opitz JC, Kettrick MA, Sullivan BJ. Recurrent neonatal herpes presenting initially with hoarseness. Am J Perinatol 1989; 6:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/51\">",
"      Cohen BA, Rowley AH, Long CM. Herpes simplex type 2 in a patient with Mollaret's meningitis: demonstration by polymerase chain reaction. Ann Neurol 1994; 35:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/52\">",
"      Conway JH, Weinberg A, Ashley RL, et al. Viral meningitis in a preadolescent child caused by reactivation of latent herpes simplex (type 1). Pediatr Infect Dis J 1997; 16:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/53\">",
"      Tedder DG, Ashley R, Tyler KL, Levin MJ. Herpes simplex virus infection as a cause of benign recurrent lymphocytic meningitis. Ann Intern Med 1994; 121:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/54\">",
"      Jensenius M, Myrvang B, St&oslash;rvold G, et al. Herpes simplex virus type 2 DNA detected in cerebrospinal fluid of 9 patients with Mollaret's meningitis. Acta Neurol Scand 1998; 98:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/55\">",
"      Steel JG, Dix RD, Baringer JR. Isolation of herpes simplex virus type I in recurrent (Mollaret) meningitis. Ann Neurol 1982; 11:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/56\">",
"      Graman PS. Mollaret's meningitis associated with acute Epstein-Barr virus mononucleosis. Arch Neurol 1987; 44:1204.",
"     </a>",
"    </li>",
"    <li>",
"     Gutierrez KM, Whitley RJ, Arvin AM. Herpes simplex virus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.813.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/58\">",
"      Centers for Disease Control and Prevention (CDC). Decline in annual incidence of varicella--selected states, 1990-2001. MMWR Morb Mortal Wkly Rep 2003; 52:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/59\">",
"      Romero JR, Newland JG. Viral meningitis and encephalitis: traditional and emerging viral agents. Semin Pediatr Infect Dis 2003; 14:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/60\">",
"      Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186 Suppl 1:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/61\">",
"      Kleinschmidt-DeMasters BK, Gilden DH. The expanding spectrum of herpesvirus infections of the nervous system. Brain Pathol 2001; 11:440.",
"     </a>",
"    </li>",
"    <li>",
"     Ross JP, Choen JI. Epstein-Barr virus. In: Infections of the Central Nervous System, 2nd ed, Scheld MW, Durack WR (Eds), Lippincott Raven, Philadelphia 1997. p.117.",
"    </li>",
"    <li>",
"     Griffiths PD, McLaughlin JE. Cytomegalovirus. In: Infections of the Central Nervous System, 2nd ed, Scheld MW, Durack WR (Eds), Lippincott Raven, Philadelphia 1997. p.107.",
"    </li>",
"    <li>",
"     Caserta MT, Hall CB. Human Herpes-6. In: Infections of the Central Nervous System, 2nd ed, Scheld MW, Durack WR (Eds), Lippincott Raven, Philadelphia 1997. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/65\">",
"      Yoshikawa T, Ihira M, Suzuki K, et al. Invasion by human herpesvirus 6 and human herpesvirus 7 of the central nervous system in patients with neurological signs and symptoms. Arch Dis Child 2000; 83:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/66\">",
"      Pohl-Koppe A, Blay M, J&auml;ger G, Weiss M. Human herpes virus type 7 DNA in the cerebrospinal fluid of children with central nervous system diseases. Eur J Pediatr 2001; 160:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/67\">",
"      Calisher CH. Medically important arboviruses of the United States and Canada. Clin Microbiol Rev 1994; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/68\">",
"      Hammer SM, Connolly KJ. Viral aseptic meningitis in the United States: clinical features, viral etiologies, and differential diagnosis. Curr Clin Top Infect Dis 1992; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/69\">",
"      Sawyer MH. Enterovirus infections: diagnosis and treatment. Pediatr Infect Dis J 1999; 18:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/70\">",
"      Gubler DJ. Arboviruses as imported disease agents: the need for increased awareness. Arch Virol Suppl 1996; 11:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/71\">",
"      Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/72\">",
"      Hayes CG. West Nile virus: Uganda, 1937, to New York City, 1999. Ann N Y Acad Sci 2001; 951:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/73\">",
"      Horga MA, Fine A. West Nile virus. Pediatr Infect Dis J 2001; 20:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/74\">",
"      Lindsey NP, Hayes EB, Staples JE, Fischer M. West Nile virus disease in children, United States, 1999-2007. Pediatrics 2009; 123:e1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/75\">",
"      Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis 2001; 33:370.",
"     </a>",
"    </li>",
"    <li>",
"     Whitley, RJ. Rabies. In: Infections of the Central Nervous System, 2nd ed, Scheld, MW, Durack, WR (Eds), Lippincott Williams &amp; Wilking, Raven, Philadelphia 1997. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/77\">",
"      Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect 2003; 36:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/78\">",
"      Newland JG, Romero JR, Varman M, et al. Encephalitis associated with influenza B virus infection in 2 children and a review of the literature. Clin Infect Dis 2003; 36:e87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/79\">",
"      Newland JG, Shah SS, Zaoutis TE. The child with aseptic meningitis. Pediatr Case Rev 2003; 3:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/80\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States, January 18-24, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/81\">",
"      Schildgen O, Glatzel T, Geikowski T, et al. Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis 2005; 11:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22809/abstract/82\">",
"      Arnold JC, Singh KK, Milder E, et al. Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J 2009; 28:1057.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5980 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22809=[""].join("\n");
var outline_f22_17_22809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Enteroviruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Human parechoviruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Herpesviruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - HSV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - VZV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - CMV and EBV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - HHV-6 and HHV-7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Arboviruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - LCMV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rabies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Less common viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/27/13757\" title=\"table 1\">",
"      Viral meningitis epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/54/36716\" title=\"table 2\">",
"      Arbovirus CNS infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/3/15420\" title=\"table 3\">",
"      Uncommon causes of viral meningitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=related_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16088?source=related_link\">",
"      Epidemiology and pathogenesis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22278?source=related_link\">",
"      Epidemiology of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=related_link\">",
"      Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=related_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14201?source=related_link\">",
"      Human herpesvirus 7 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/35/16946?source=related_link\">",
"      Patient information: Aseptic meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/34/28194?source=related_link\">",
"      Patient information: Viral meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38023?source=related_link\">",
"      St. Louis encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=related_link\">",
"      Viral meningitis: Management, prognosis, and prevention in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_17_22810="Initial therapy and prognosis of bacterial meningitis in adults";
var content_f22_17_22810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial therapy and prognosis of bacterial meningitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22810/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22810/contributors\">",
"     Allan R Tunkel, MD, PhD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22810/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22810/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/17/22810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/17/22810/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/17/22810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis is a medical emergency, and immediate steps must be taken to establish the specific cause and initiate effective therapy. The mortality rate of untreated disease approaches 100 percent and, even with optimal therapy, there is a high failure rate.",
"   </p>",
"   <p>",
"    The possible presence of bacterial meningitis is suggested by the symptoms of fever, altered mental status, headache, and nuchal rigidity. Although one or more of these findings are absent in many patients with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], virtually all patients (99 to 100 percent) have at least one of the classic triad of fever, neck stiffness, and altered mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial therapy and prognosis of bacterial meningitis will be reviewed here. The epidemiology, pathogenesis, clinical features, diagnosis, treatment of specific pathogens, and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in the management of bacterial meningitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link\">",
"     \"Epidemiology of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38549?source=see_link\">",
"     \"Pathogenesis and pathophysiology of bacterial meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, the following historical information should be obtained before antibiotic treatment of presumed bacterial meningitis is instituted. Has the patient had or does the patient have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serious drug allergies",
"     </li>",
"     <li>",
"      Recent exposure to someone with meningitis",
"     </li>",
"     <li>",
"      A recent infection (especially respiratory or ear infection)",
"     </li>",
"     <li>",
"      Recent use of antibiotics",
"     </li>",
"     <li>",
"      Recent travel, particularly to areas with endemic meningococcal disease such as sub-Saharan Africa",
"     </li>",
"     <li>",
"      A history of injection drug use",
"     </li>",
"     <li>",
"      A progressive petechial or ecchymotic rash, which would be most suggestive of meningococcal infection",
"     </li>",
"     <li>",
"      A history of recent or remote head trauma",
"     </li>",
"     <li>",
"      Otorrhea or rhinorrhea",
"     </li>",
"     <li>",
"      HIV infection or risk factors",
"     </li>",
"     <li>",
"      Any other immunocompromising conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial blood tests should include a complete blood count with differential, and two sets of blood cultures, which are positive in 50 to 90 percent of adults with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. The rate of positive blood cultures is lowest with meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/6\">",
"     6",
"    </a>",
"    ], and cultures obtained after antimicrobials are much less likely to be positive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=see_link\">",
"     \"Blood cultures for the detection of bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial approach to management in a patient with suspected bacterial meningitis includes performance of a lumbar puncture to determine whether the cerebrospinal fluid (CSF) findings are consistent with the diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef50114 \" href=\"UTD.htm?11/41/11935\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"     9",
"    </a>",
"    ]. CSF should be sent for cell count and differential, glucose and protein concentrations, Gram stain, and culture. Characteristic findings in bacterial meningitis include a CSF glucose concentration &lt;45",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    a CSF to serum glucose ratio of &le;0.4, a protein concentration of 100 to 500",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and a white blood cell count above",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    usually composed primarily of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the spectrum of CSF values in bacterial meningitis is so wide that the absence of one of more of these findings is of little value (",
"    <a class=\"graphic graphic_table graphicRef76324 \" href=\"UTD.htm?13/55/14204\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This was illustrated in a review of 296 episodes of community-acquired bacterial meningitis: 50 percent had a CSF glucose above 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.2",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    44 percent had a CSF protein below 200",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    and 13 percent had a CSF white cell count below",
"    <span class=\"nowrap\">",
"     100/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/3\">",
"     3",
"    </a>",
"    ]. In another series of 696 episodes of community-acquired bacterial meningitis, 12 percent had none of the characteristic CSF findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'CSF analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another modality used during the evaluation for bacterial meningitis is polymerase chain reaction (PCR) of the CSF. Although PCR has high sensitivity and specificity for the detection of bacterial pathogens such as S. pneumoniae in the CSF, problems with false-positive results have been reported. Further refinements in this technique may make it useful for the diagnosis of bacterial meningitis, especially when results of CSF Gram stain and culture are negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'Polymerase chain reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of general principles of antibiotic therapy in patients with bacterial meningitis. The most important initial issues are avoidance of delay in administering therapy and the choice of drug regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Avoidance of delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy, along with adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    when indicated, should be initiated immediately after the performance of the lumbar puncture (LP) or, if a computed tomography (CT) scan of the head is to be performed before LP, immediately after blood cultures are obtained (",
"    <a class=\"graphic graphic_algorithm graphicRef50114 \" href=\"UTD.htm?11/41/11935\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'Indications for CT scan before LP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Effects of delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delay in the administration of antibiotics can have adverse effects, as illustrated in the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/2,10-12\">",
"     2,10-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study that included 269 adults with bacterial meningitis, three baseline prognostic markers at the time of initiation of antibiotics - hypotension, altered mental status, and seizures - were predictive of an adverse outcome (defined as in-hospital mortality or a neurologic deficit at discharge) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/2\">",
"       2",
"      </a>",
"      ]. Delay in initial antibiotics in the emergency department (median delay of four hours) was associated with a worsening of these markers in about 15 percent of patients. Those patients whose delay in antibiotic therapy allowed their disease to advance from having zero or one to having two or three poor prognostic indicators had a significant increase in adverse outcomes.",
"     </li>",
"     <li>",
"      In a prospective study of 156 patients with pneumococcal meningitis, a delay in antibiotic treatment of more than three hours after hospital admission was a strong and independent risk factor for mortality (OR 14.1; 95% CI: 3.9 to 50.9). Delayed therapy was a greater risk factor than the isolation of a penicillin-resistant strain (OR 6.83; 95% CI 2.94-20.8) or a higher disease severity (OR 1.12; 95% CI 1.07-1.15) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort study of 286 patients with community-acquired bacterial meningitis, early and adequate administration of antibiotic therapy in relation to the onset of overt signs of meningitis was independently associated with a favorable outcome, defined as mild or no disability (OR 11.2, 95% CI 4.4-32.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 119 adults with bacterial meningitis examined the association between mortality and the time elapsed between emergency department presentation and antibiotic administration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/11\">",
"       11",
"      </a>",
"      ]. The adjusted odds ratio (OR) for mortality was 8.4 for a door-to-antibiotic time greater than six hours when the patient presented afebrile and 12.6 for patients with severely impaired mental status at presentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Causes of delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important causes of delay in the initiation of antimicrobial therapy include atypical clinical presentation and delay due to cranial imaging. It is important to note that antimicrobial therapy should NOT be delayed if imaging is performed prior to lumbar puncture.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical presentation &mdash; In the retrospective study of 119 adults with bacterial meningitis described above, the most dramatic clinical predictor of death was the absence of fever at presentation (odds ratio 39.4, 95% CI 4.3-358.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/11\">",
"       11",
"      </a>",
"      ]. This finding, along with other \"atypical features\" (eg, lack of headache or neck stiffness), accounts for some of the delay in making the diagnosis and initiating therapy. While a deliberate delay of therapy is never warranted, the diagnosis can be quite challenging in cases with atypical features. Lowering the threshold for initiation of therapy may be prudent, but there is no clear guideline that will identify bacterial meningitis in patients with atypical features without some risk of over-treatment. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Prediction of risk'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Delay due to imaging &mdash; An important cause of delayed therapy in patients with suspected bacterial meningitis is performance of a computed tomography (CT) scan of the head to exclude an occult mass lesion that could lead to cerebral herniation during subsequent CSF removal [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"       9",
"      </a>",
"      ]. Should LP be delayed by the need for cranial imaging in patients suspected of having bacterial meningitis, blood cultures should be obtained and antibiotics should be administered empirically along with adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      just prior to or concomitant with the first antibiotic dose. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"       \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although commonly performed, a screening CT scan of the head is NOT necessary in the majority of patients. In two large series, 3 to 5 percent of patients had a finding that was a contraindication to LP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. Risk factors included a suspicious history (eg, immunocompromised state, history of previous central nervous system disease, or a seizure within the previous week) as well as certain findings on neurologic examination (eg, reduced level of consciousness, focal motor or cranial abnormalities, and papilledema).",
"   </p>",
"   <p>",
"    In the retrospective study of 119 adults with bacterial meningitis noted above, withholding antibiotics until a CT scan and lumbar puncture were done was strongly associated with a delay of &gt;6 h to the first dose of antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/11\">",
"     11",
"    </a>",
"    ]. What cannot be measured as easily is the number of excess doses of glucocorticoids and antibiotics administered in patients without meningitis, but with clinical features suggestive of meningitis, at the time of presentation. Some excess treatment should be expected in order to optimize the outcome of patients with bacterial meningitis.",
"   </p>",
"   <p>",
"    Although the use of antimicrobial therapy before LP has an adverse impact on the yield of CSF Gram stain and culture, a pathogen can still be identified in the CSF in the majority of patients up to several hours after the administration of antibiotics, with the possible exception of meningococcal infection. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'Lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotic regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three general requirements of antibiotic therapy for bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of bactericidal drugs effective against the infecting organism",
"     </li>",
"     <li>",
"      Use of drugs that enter the CSF, since the blood-brain barrier prevents macromolecule entry into the CSF",
"     </li>",
"     <li>",
"      Structuring the regimen to optimize bactericidal efficacy based on the pharmacodynamic characteristics of the antimicrobial agent(s)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bactericidal drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the CSF is a site of impaired humoral immunity, a fundamental principle of therapy of bacterial meningitis is that antibiotics must achieve a bactericidal effect within CSF to result in optimal microbiologic cure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/16\">",
"     16",
"    </a>",
"    ]. In an animal model of bacterial meningitis, bactericidal antibiotic therapy resulted in optimal microbiologic cure and survival in animals with pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/17\">",
"     17",
"    </a>",
"    ]. This principle is also supported by clinical observations of poor outcomes in patients receiving bacteriostatic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Drug entry into CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic penetration into CSF depends to a large extent on the status of the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/19\">",
"     19",
"    </a>",
"    ]. For example, when the blood-brain barrier is normal, most beta-lactam agents (eg, penicillin) penetrate poorly. However, in the presence of meningeal inflammation, CSF penetration is enhanced likely as a result of separation of intercellular tight junctions and increased numbers of pinocytotic vesicles in cerebral microvascular endothelial cells. As inflammation subsides, antibiotic entry decreases. Thus, maximal parenteral doses should be continued throughout the course of therapy to maintain adequate CSF concentrations. Antibiotic entry is also enhanced with drugs that have a high lipid solubility, low molecular weight, low protein binding, and low ionization at physiologic pH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link&amp;anchor=H5#H5\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Blood-brain barrier'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are specific dosing recommendations for the antibiotics used to treat bacterial meningitis in order to attain maximal concentrations in the CSF. In some cases, higher doses of antibiotics are used for bacterial meningitis than for other infections (",
"    <a class=\"graphic graphic_table graphicRef60707 \" href=\"UTD.htm?17/45/18141\">",
"     table 2B",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For antibiotics that exhibit time-dependent antimicrobial activity (eg, beta-lactams,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ), the bactericidal activity depends upon the time that the agent is above the minimal inhibitory concentration (MIC) as a proportion of the dosing interval [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/15\">",
"     15",
"    </a>",
"    ]. For agents that exhibit concentration-dependent antimicrobial activity (eg, aminoglycosides), killing occurs over a wide range of antimicrobial concentrations and there is a prolonged recovery period (ie, the post-antibiotic effect) after drug concentrations fall below the MIC during which regrowth of bacteria is delayed. The CSF pharmacodynamics of fluoroquinolones are more complicated, however, and features of both time-dependency and concentration-dependency have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic selection must be empiric immediately after CSF is obtained or when lumbar puncture is delayed. In such patients, antibiotic therapy needs to be directed at the most likely bacteria based upon patient age and underlying comorbid disease (",
"    <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/3\">",
"     3",
"    </a>",
"    ]. Knowledge of local susceptibility patterns also may be important. Empiric regimens are discussed in detail below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Empiric therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once the CSF Gram stain results are available, the antibiotic regimen should be tailored to cover the most likely pathogen. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Regimens based upon gram stain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the CSF findings are consistent with the diagnosis of acute bacterial meningitis, but the Gram stain is negative, empiric antibiotic therapy should be continued. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Empiric therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The antibiotic regimen should be modified further, when indicated, based on the CSF culture and susceptibility results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the general limitation in antibiotic penetration into the CSF, all patients should be treated with intravenous antibiotics. Oral antibiotics should be avoided since the dose and tissue concentrations tend to be considerably lower than with parenteral agents. An exception can be made for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , which is useful as a synergistic agent for treatment of meningitis caused by beta-lactam-resistant S. pneumoniae or coagulase-negative staphylococcus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168234278\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibiotic therapy for bacterial meningitis depends upon the causative pathogen. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adjunctive dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent neurologic sequelae, such as hearing loss and focal neurologic deficits, are not uncommon in survivors of bacterial meningitis, particularly patients with pneumococcal meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early intravenous administration of glucocorticoids (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) has been evaluated as adjunctive therapy in an attempt to diminish the rate of hearing loss, other neurologic complications, and mortality. Based upon clinical trial data from Europe, the main indication for dexamethasone therapy in adults is known or suspected pneumococcal meningitis. Since the etiology of bacterial meningitis is not usually known at the time of treatment initiation, dexamethasone is administered to patients in the developed world with suspected bacterial meningitis in whom the organism is unknown. Dexamethasone should only be continued if the CSF Gram stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the CSF or blood cultures reveal S. pneumoniae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the entry of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    into the CSF may be reduced by the decrease in inflammation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is sometimes added in patients receiving dexamethasone. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link&amp;anchor=H9#H9\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\", section on 'Antibiotic regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy in the developing world varies with the patient population. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link&amp;anchor=H4#H4\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\", section on 'In developing regions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The empiric approach to antibiotic selection in patients with suspected bacterial meningitis is directed at the most likely bacteria based on the patient's age and host factors (",
"    <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. There have been no randomized trials in adults regarding the empiric therapy of bacterial meningitis. Treatment recommendations are based upon in vitro susceptibility and pharmacodynamic data, randomized trials in children, and accumulated clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Causative organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a United States surveillance study performed by the Centers for Disease Control and Prevention via the Emerging Infections Program Network, between 2003 and 2007, 1083 cases of bacterial meningitis were reported in adults; S. pneumoniae was responsible for 71 percent of cases, Neisseria meningitidis for 12 percent, group B streptococcus for 7 percent, Haemophilus influenzae for 6 percent, and Listeria monocytogenes for 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/21\">",
"     21",
"    </a>",
"    ]. Importantly, in adults, the incidence of bacterial meningitis caused by Listeria monocytogenes rises with increasing age. For this reason, adults &gt;50 years of age should receive an antibiotic with activity against L. monocytogenes (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ) as part of the empiric regimen. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'No known immune deficiency'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The epidemiology of bacterial meningitis and adults and children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Community-acquired'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Empiric regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The empiric approach to antibiotic selection in patients with suspected bacterial meningitis is directed at the most likely bacteria based on the patient's age and underlying disease status (",
"    <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9,20\">",
"     9,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selected third-generation cephalosporins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , are the beta-lactams of choice in the empiric treatment of meningitis. These agents been demonstrated to be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    in randomized trials of bacterial meningitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. These drugs have consistent CSF penetration and potent activity against the major pathogens of bacterial meningitis, with the notable exceptions of Listeria monocytogenes and some penicillin-resistant strains of S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. With the worldwide increase in the prevalence of penicillin-resistant pneumococci,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be added to cefotaxime or ceftriaxone as empiric treatment until culture and susceptibility results are available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    , a third-generation cephalosporin with broad in vitro activity against gram-negative bacteria including Pseudomonas aeruginosa, is much less active against penicillin-resistant pneumococci than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/29\">",
"     29",
"    </a>",
"    ]. However, a fourth-generation cephalosporin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , has been shown to be safe and therapeutically equivalent to cefotaxime for the treatment of bacterial meningitis in infants and children, and can be considered a suitable alternative to cefotaxime or ceftriaxone when broad activity against both the pneumococcus and Gram negative bacteria, such as P. aeruginosa, is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     No known immune deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus pneumoniae, Neisseria meningitidis, and, less often, Haemophilus influenzae and group B streptococcus are the most likely causes of community-acquired bacterial meningitis in otherwise healthy adults up to the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/31\">",
"     31",
"    </a>",
"    ]. Individuals over aged 50 years are also at increased risk of Listeria monocytogenes meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Causative organisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Such patients, without evidence of renal insufficiency, should be treated empirically with the following regimen until culture and susceptibility data are available (",
"    <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      &mdash; 2 g IV every 12 hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      &mdash; 2 g IV every four to six hours",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"       <br/>",
"       <br/>",
"       PLUS",
"      </span>",
"     </li>",
"     <li>",
"      In adults &gt;50 years of age,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      &mdash; 2 g IV every four hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third-generation cephalosporin should be continued even if in vitro tests demonstrate intermediate susceptibility or resistance to cephalosporins, since they may provide synergy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoroquinolones have not been extensively studied for the treatment of bacterial meningitis. They achieve reasonably high CSF concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"     9",
"    </a>",
"    ], and there is some anecdotal evidence of efficacy in animal models and in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9,34\">",
"     9,34",
"    </a>",
"    ]. One fluoroquinolone, trovafloxacin, was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , in a multicenter randomized trial of 311 children with bacterial meningitis; the overall efficacy (CSF sterilization and clinical success) of both treatment groups was similar [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/35\">",
"     35",
"    </a>",
"    ]. Although trovafloxacin is no longer utilized because of its association with serious hepatotoxicity, these results suggest the potential usefulness of newer fluoroquinolones in the treatment of bacterial meningitis. However, fluoroquinolones are not recommended as part of standard therapy unless unusual conditions, such as multiple severe drug allergies or highly resistant organisms, are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Impaired cellular immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with impaired cell-mediated immunity (due, for example, to lymphoma, cytotoxic chemotherapy, or high-dose glucocorticoids), coverage must be directed against Listeria monocytogenes and gram-negative bacilli (including Pseudomonas aeruginosa) as well as Streptococcus pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An appropriate regimen in patients with normal renal function is (",
"    <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"     table 2A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      &mdash; 2 g IV every four hours",
"      <br/>",
"      <br/>",
"      PLUS EITHER",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Healthcare-associated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of causative organisms is appreciably different in patients with healthcare-associated meningitis (ie, following head trauma or neurosurgery; in patients with internal or external ventricular drains) compared with community-acquired meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/37\">",
"     37",
"    </a>",
"    ]. This was illustrated in a review of 197 episodes of healthcare-associated meningitis (most of which were related to recent neurosurgery or the presence of neurosurgical devices) seen between 1962 and 1988 in which gram-negative bacilli accounted for 33 percent of episodes, and streptococci, Staphylococcus aureus, and coagulase-negative staphylococci accounted for 9 percent each [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, S. pneumoniae, N. meningitidis, and L. monocytogenes accounted for only 8 percent.",
"   </p>",
"   <p>",
"    Similar pathogens were involved in a later series of 6243 consecutive craniotomies performed between 1997 and 1999; patients with ventriculitis related to a device were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/38\">",
"     38",
"    </a>",
"    ]. Meningitis occurred in 1.5 percent of procedures. When comparing patients from periods before and after antimicrobial prophylaxis was given (to prevent wound infection), prophylaxis had no effect on the rate of meningitis but did affect the cause of meningitis. Without prophylaxis most cases were caused by cutaneous organisms (S. aureus, coagulase-negative staphylococci, and P. acnes), whereas with prophylaxis most cases were caused by non-cutaneous organisms (Enterobacteriaceae &gt; streptococci and Pseudomonas aeruginosa &gt; coagulase-negative staphylococci, S. aureus, and P. acnes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Neurosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon such observations, empiric therapy must cover both gram-positive and gram-negative (such as Klebsiella pneumoniae and Pseudomonas aeruginosa) pathogens (",
"    <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"     table 2A-B",
"    </a>",
"    ). Appropriate regimens in patients with normal renal function, pending culture results and susceptibility testing, are [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9,37\">",
"     9,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"       <br/>",
"       <br/>",
"       PLUS",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important clinical question is the safety of withdrawing antibiotic therapy if the CSF culture results are negative and suggest aseptic rather than bacterial meningitis post-neurosurgery. A consensus conference recommended empiric antibiotic therapy in all patients with clinical and laboratory features suggestive of postoperative meningitis; such therapy can be discontinued at 48 to 72 hours if the CSF culture is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of this approach has not been assessed in randomized trials but was evaluated in a cohort study of patients with meningitis at different time periods following neurosurgery or ear nose and throat surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/40\">",
"     40",
"    </a>",
"    ]. Between 1998 and most of 2003, the control period, guidelines were lacking or not implemented. From the end of 2003 through mid-2005, an interventional protocol was followed in which predefined intravenous antibiotic therapy was discontinued if the meningitis was considered aseptic as defined by a negative CSF culture on the third day.",
"   </p>",
"   <p>",
"    There were 21 cases of bacterial meningitis and 54 of aseptic meningitis; no patient had an intracranial device. The duration of therapy was not different in the two time periods for bacterial meningitis but was significantly shorter with the interventional protocol in the later period for aseptic meningitis (3.5 versus 11.5 days). All episodes of meningitis were cured and complications were rare in both time periods.",
"   </p>",
"   <p>",
"    An important limitation to this observational study is that it is unclear how many patients received perioperative antimicrobial therapy. This could have major implications for a negative CSF bacterial culture postoperatively, since the CSF may be infected but partially treated. For this reason, cessation of antibiotics is NOT recommended in patients who have received prior or are receiving concurrent antibiotic therapy with a negative CSF culture and who are suspected of having meningitis based on clinical and laboratory findings (eg, CSF pleocytosis).",
"   </p>",
"   <p>",
"    Infections of CNS shunts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Beta-lactam allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to therapy in patients with antibiotic allergies is challenging given the importance of early initiation of therapy and the crucial role of beta-lactam antibiotics in the therapy of bacterial meningitis. Although it is optimal to desensitize patients with a history of an IgE-mediated (anaphylactic) reaction to beta-lactams who require therapy with this antibiotic class, an alternative regimen must be used while the desensitization is being performed. Furthermore, the decision of whether to desensitize a patient should be based on the Gram stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture data, the latter of which can take several days to yield an organism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For empiric coverage in patients with severe beta-lactam allergies and normal renal function, the following regimen can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      &mdash; 400 mg IV once daily",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      If Listeria coverage is required (in patients &gt;50",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in those with defects in cell-mediated immunity or other risk factors),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      &ndash; 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component) IV every 6 to 12 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Empiric treatment during epidemics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemics of meningitis due to N. meningitidis are reported almost every year from sub-Saharan Africa. The empiric therapy recommended by the World Health Organization for meningococcal meningitis during epidemics is one or two intramuscular injections of long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    (oily suspension), although intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    is an acceptable alternative. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Empiric treatment during epidemics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     REGIMENS BASED UPON GRAM STAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rather than empiric therapy, intravenous antibiotics should be directed at the presumed pathogen if the Gram stain is diagnostic (",
"    <a class=\"graphic graphic_table graphicRef75922 graphicRef60707 \" href=\"UTD.htm?5/11/5310\">",
"     table 2B-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"     9",
"    </a>",
"    ]. If indicated, antibiotic therapy should then be modified once the CSF culture and in vitro susceptibility studies are available (",
"    <a class=\"graphic graphic_table graphicRef81209 graphicRef60707 \" href=\"UTD.htm?7/17/7455\">",
"     table 2B, 2D",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If gram-positive cocci are seen on the Gram stain of a patient with community-acquired meningitis, Streptococcus pneumoniae should be the suspected pathogen.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      plus a third-generation cephalosporin (either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ) should be administered. However, in the setting of neurosurgery or head trauma within the past month, a neurosurgical device, or a CSF leak, Staphylococcus aureus and coagulase-negative staphylococci are more common and therapy with vancomycin is warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If gram-negative cocci are seen, Neisseria meningitidis is the probable pathogen.",
"     </li>",
"     <li>",
"      Gram-positive bacilli suggest Listeria monocytogenes.",
"     </li>",
"     <li>",
"      Gram-negative bacilli usually represent Enterobacteriaceae (eg, Klebsiella spp, Escherichia coli) in cases of community-acquired meningitis. However, if there is a history of neurosurgery or head trauma within the past month, or if a neurosurgical device is present,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      should be replaced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      since such patients are at greater risk for Pseudomonas aeruginosa and Acinetobacter spp infection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/37\">",
"       37",
"      </a>",
"      ]; given issues of cephalosporin resistance with Acinetobacter spp, meropenem would be a more appropriate empiric choice when infection caused by this organism is suspected [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, resistance patterns at a given hospital should be taken into account when choosing an empiric regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     THERAPY FOR SPECIFIC PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directed therapy against a specific organism is recommended when the clinical presentation and results of the CSF Gram stain are unequivocal (",
"    <a class=\"graphic graphic_table graphicRef75922 \" href=\"UTD.htm?10/57/11164\">",
"     table 2C",
"    </a>",
"    ) or the cultures are already positive (",
"    <a class=\"graphic graphic_table graphicRef81209 \" href=\"UTD.htm?11/55/12158\">",
"     table 2D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/29\">",
"     29",
"    </a>",
"    ]. If, on the other hand, empiric therapy is begun, the regimen should be adjusted, if necessary, once the culture results are available (",
"    <a class=\"graphic graphic_table graphicRef81209 \" href=\"UTD.htm?11/55/12158\">",
"     table 2D",
"    </a>",
"    ). Recommended dosages for use in patients with normal renal and hepatic function are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef60707 \" href=\"UTD.htm?17/45/18141\">",
"     table 2B",
"    </a>",
"    ). The recommended treatment regimens for specific pathogens are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful management of fluid and electrolyte balance is important, since both over- and under-hydration are associated with adverse outcomes.",
"   </p>",
"   <p>",
"    A meta-analysis evaluated three randomized controlled trials of treatment of differing volumes of fluid (maintenance versus restricted fluid) given in the initial management of bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/42\">",
"     42",
"    </a>",
"    ]. The largest trial was conducted in a setting with a high mortality rate. There was no significant difference between the two groups in number of deaths, or acute severe or mild to moderate neurological sequelae. However, when neurological sequelae were defined further, there was a statistically significant difference in favor of the maintenance fluid group in regard to spasticity (relative risk [RR] 0.50, 95% CI 0.27-0.93), seizures at both 72 hours (RR 0.59, 95% CI 0.42-0.83) and 14 days (RR 0.19, 95% CI 0.04-0.88), and chronic severe neurological sequelae at three months follow up (RR 0.42, 95% CI 0.20-0.89). Thus, there is evidence that the use of intravenous maintenance fluids is preferred to restricted fluid intake in the first 48 hours in settings with high mortality rates and where patients present late. There is insufficient evidence to guide practice in other settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Reduction of intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bacterial meningitis who have elevations of intracranial pressure (ICP), and who are stuporous or comatose, may benefit from insertion of an ICP monitoring device [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/28,43\">",
"     28,43",
"    </a>",
"    ]. Pressures exceeding 20 mm Hg are abnormal and should be treated; there is also rationale for treating smaller pressure elevations (ie, above 15 mm Hg) to avoid larger elevations that can lead to cerebral herniation and irreversible brainstem injury.",
"   </p>",
"   <p>",
"    Methods to reduce ICP include elevating the head of the bed to 30&ordm; and hyperventilation to maintain PaCO2 between 27 and 30 mm Hg. Another method that has been evaluated for reducing ICP is oral administration of the hyperosmolar agent, glycerol. However, a randomized trial in adults with bacterial meningitis in Malawi (a resource-poor country with high HIV prevalence) was stopped early because planned interim analysis demonstrated increased mortality by day 40 in the glycerol group (63 versus 49 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/44\">",
"     44",
"    </a>",
"    ]. The reason for this finding is unclear, but might relate to an increased incidence of seizures in the patients who received glycerol. Another possible reason could be a rebound increase in ICP as the drug is eliminated, although ICP was not monitored in this trial. In contrast to this trial involving adults, some studies using glycerol have shown promising results in children with bacterial meningitis, although further data are needed before it can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link&amp;anchor=H17#H17\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\", section on 'Glycerol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a trial of 15 patients with bacterial meningitis in whom intracranial pressure was monitored, pressure was significantly lowered by a broad range of measures that utilized unconventional volume-targeted intracranial pressure management [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/45\">",
"     45",
"    </a>",
"    ]. These included sedation, glucocorticoids, normal fluid and electrolyte homeostasis, blood transfusion, albumin infusion, decrease of mean arterial pressure, treatment with a prostacyclin analog, and eventually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    , ventriculostomy, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    . In those not surviving their episode of bacterial meningitis, mean intracranial pressure was significantly higher. However, given that this was not a comparative trial, the results must be interpreted with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     REPEAT CSF ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited utility to routine repeat LP to assess the response to therapy in adults with bacterial meningitis. This was illustrated in a review of 165 adults with meningitis who underwent an end of treatment LP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/46\">",
"     46",
"    </a>",
"    ]. Wide ranges of glucose and protein concentrations and cell counts were found at the end of treatment in patients who were ultimately shown to be cured without further therapy. In addition, repeat CSF examination failed to detect relapse in the two patients who relapsed following treatment, and the CSF test results led to unnecessary testing in 13 patients with abnormal CSF findings at the end of therapy. The authors concluded that clinical signs of improvement were a better indicator of response to therapy than the results of CSF analysis after treatment had been completed.",
"   </p>",
"   <p>",
"    Although not routinely recommended, there are settings in which repeat LP should be performed in patients with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When there is no evidence of improvement by 48 hours after the initiation of appropriate therapy.",
"     </li>",
"     <li>",
"      Two to three days after the initiation of therapy of meningitis due to microorganisms resistant to standard antimicrobial agents (eg, penicillin-resistant pneumococcal infection), especially for those who have also received adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      therapy and are not responding as expected, or for infection caused by a gram-negative bacillus, which is much more common with healthcare-associated infection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/3,37\">",
"       3,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Persistent fever for more than eight days without another explanation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeat CSF cultures should be sterile. For patients in whom repeat cultures are positive despite appropriate therapy with parenteral antibiotic therapy, administration of intrathecal (or intraventricular) antibiotics may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an appreciable mortality rate associated with bacterial meningitis even with the administration of appropriate antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate increases linearly with increasing age. In a United States population-based surveillance study between 2003 and 2007, the case-fatality rate of bacterial meningitis in adults was 16.4 percent; among patients between 18 and 34 years of age, the case-fatality rate was 8.9 percent compared with 22.7 percent in patients &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/21\">",
"     21",
"    </a>",
"    ]. The overall case-fatality rate did not change significantly between 1998-1999 and 2006-2007. &nbsp;",
"   </p>",
"   <p>",
"    Outcomes also vary depending upon the organism. The following observations from different time periods illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 493 episodes of bacterial meningitis in 445 adults seen at a single center in the United States from 1962 to 1988, the overall mortality rate was 25 percent and did not vary over the course of the study [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/3\">",
"       3",
"      </a>",
"      ]. The mortality rate was higher with healthcare-associated compared to community-acquired infection (35 versus 25 percent), and was higher with infection due to S. pneumoniae and L. monocytogenes compared to N. meningitidis (28 and 32 versus 10 percent).",
"     </li>",
"     <li>",
"      In a series of 248 patients seen in 1995 in acute care hospitals in 22 counties in four states in the United States, the mortality rate was highest with S. pneumoniae and L. monocytogenes (21 and 15 percent, respectively) and lowest with N. meningitidis (3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from the Netherlands evaluated 696 cases of community-acquired acute bacterial meningitis seen between 1998 and 2002 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/5\">",
"       5",
"      </a>",
"      ]. The overall mortality rate was significantly higher with pneumococcal compared to meningococcal meningitis (30 versus 7 percent). In addition, an unfavorable outcome was six times more common with pneumococcal meningitis, even after adjustment for other clinical predictors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Neurologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications are not uncommon in adults with bacterial meningitis. In a review of 493 episodes of bacterial meningitis in adults, for example, 28 percent of community-acquired episodes resulted in one or more neurologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/3\">",
"     3",
"    </a>",
"    ]. The neurologic complications of bacterial meningitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired mental status",
"     </li>",
"     <li>",
"      Increased intracranial pressure and cerebral edema",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Focal neurologic deficits (eg, cranial nerve palsy, hemiparesis)",
"     </li>",
"     <li>",
"      Cerebrovascular abnormalities",
"     </li>",
"     <li>",
"      Sensorineural hearing loss",
"     </li>",
"     <li>",
"      Intellectual impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Prediction of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline features can be used to estimate the individual patient's risk for an adverse outcome. A prognostic model was derived from a cohort of 176 adults and then validated in another cohort of 93 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/2\">",
"     2",
"    </a>",
"    ]. The in-hospital mortality was 27 percent, and 9 percent had a neurologic deficit at discharge. Three baseline clinical features - hypotension, altered mental status, and seizures - were independently associated with an adverse outcome (defined as in-hospital death or neurologic deficit at discharge) and stratified the patients into three risk groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (no clinical risk factors) &mdash; 9 percent adverse outcome",
"     </li>",
"     <li>",
"      Intermediate risk (one clinical risk factor) &mdash; 33 percent adverse outcome",
"     </li>",
"     <li>",
"      High risk (two or three risk factors) &mdash; 56 percent adverse outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional risk factor for an adverse outcome in this report was advancement from low or intermediate risk to high risk in the emergency department prior to the administration of antibiotics. Although this finding supports the recommendation to avoid delays in antimicrobial therapy in patients with suspected bacterial meningitis, it is also consistent with the hypothesis that severely ill patients at the start may have an adverse outcome regardless of the timing of initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/17/22810/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       \"Patient information: Bacterial meningitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial meningitis is a medical emergency, and immediate steps must be taken to establish the specific cause and initiate effective therapy. The mortality rate of untreated disease approaches 100 percent and, even with optimal therapy, there is a high failure rate. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If possible, crucial historical information (eg, serious drug allergies, recent exposure to an individual with meningitis), should be obtained before antibiotic treatment of presumed bacterial meningitis is instituted. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial blood tests should include a complete blood count with differential, and two sets of blood cultures. The initial approach to management in a patient with suspected bacterial meningitis includes performance of a lumbar puncture (LP) to determine whether the cerebrospinal fluid (CSF) findings are consistent with the diagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three general requirements of antibiotic therapy for bacterial meningitis: use of bactericidal drugs effective against the infecting organism, use of drugs that enter the CSF, and use of drugs with optimal pharmacodynamics. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotic regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that antibiotic therapy be initiated immediately after the performance of the lumbar puncture (LP) or, if a computed tomography scan is to be performed before LP, immediately after blood cultures are obtained (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      should be given shortly before or at the same time as the first dose of antibiotics, when indicated. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Avoidance of delay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults in the developed world with suspected bacterial meningitis in whom the organism is unknown or Streptococcus pneumoniae is confirmed, we recommend administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Dexamethasone should be continued if the CSF Gram stain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the CSF or blood cultures reveal S. pneumoniae.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      is added to the regimen in patients receiving dexamethasone under certain circumstances. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"       \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once the CSF Gram stain results are available, the antibiotic regimen should be tailored to cover the most likely pathogen. If the CSF findings are consistent with the diagnosis of acute bacterial meningitis, but the Gram stain is negative, empiric antibiotic therapy should be continued. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Regimens based upon gram stain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The antibiotic regimen should be modified further, when indicated, based on the CSF culture and susceptibility results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"       \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Empiric antibiotics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic selection must be empiric immediately after CSF is obtained or when lumbar puncture is delayed. The empiric approach to antibiotic selection in patients with suspected bacterial meningitis is directed at the most likely bacteria based on the patient's age and underlying disease status (",
"      <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Empiric regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     No known immunodeficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptococcus pneumoniae, Neisseria meningitidis, and, less often, Haemophilus influenzae and group B streptococcus are the most likely causes of community-acquired bacterial meningitis in otherwise healthy adults up to the age of 60. Individuals aged over 50 years are also at substantial risk of Listeria monocytogenes meningitis. Patients without known immune deficiency and with normal renal function should be treated empirically with the following regimen until culture and susceptibility data are available (",
"      <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"       table 2A-B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      &mdash; 2 g IV every 12 hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      &mdash; 2 g IV every four to six hours",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      In adults &gt;50 years of age,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      &mdash; 2 g IV every four hours (see",
"      <a class=\"local\" href=\"#H19\">",
"       'No known immune deficiency'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Impaired cell-mediated immunity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with impaired cell-mediated immunity (due, for example, to lymphoma, cytotoxic chemotherapy, or high-dose glucocorticoids), coverage must be directed against Listeria monocytogenes and gram-negative bacilli (including Pseudomonas aeruginosa) as well as Streptococcus pneumoniae. An appropriate regimen in patients with normal renal function is (",
"      <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"       table 2A-B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      &mdash; 2 g IV every four hours",
"      <br/>",
"      <br/>",
"      PLUS EITHER",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      &mdash; 2 g IV every eight hours (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Impaired cellular immunity'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Healthcare-associated meningitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empiric therapy for healthcare-associated meningitis must cover both gram-positive and gram-negative (such as Klebsiella pneumoniae and Pseudomonas aeruginosa) pathogens (",
"      <a class=\"graphic graphic_table graphicRef71968 graphicRef60707 \" href=\"UTD.htm?24/18/24878\">",
"       table 2A-B",
"      </a>",
"      ). An appropriate regimen in patients with normal renal function is:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      &mdash; 2 g IV every eight hours",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      &mdash; 2 g IV every eight hours (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Healthcare-associated infection'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Allergy to beta-lactams",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For empiric coverage in patients with severe beta-lactam allergies and normal renal function, we suggest (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      adjust dose to achieve vancomycin serum trough concentrations of 15 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"       <br/>",
"       <br/>",
"       PLUS",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      &mdash; 400 mg IV once daily",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      If Listeria coverage is required (in patients &gt;50 years of age",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in those with defects in cell-mediated immunity),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      &ndash; 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component) IV every 6 to 12 hours",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/1\">",
"      de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/2\">",
"      Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/3\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/4\">",
"      Attia J, Hatala R, Cook DJ, Wong JG. The rational clinical examination. Does this adult patient have acute meningitis? JAMA 1999; 282:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/5\">",
"      van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/6\">",
"      Geiseler PJ, Nelson KE, Levin S, et al. Community-acquired purulent meningitis: a review of 1,316 cases during the antibiotic era, 1954-1976. Rev Infect Dis 1980; 2:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/7\">",
"      Talan DA, Hoffman JR, Yoshikawa TT, Overturf GD. Role of empiric parenteral antibiotics prior to lumbar puncture in suspected bacterial meningitis: state of the art. Rev Infect Dis 1988; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/8\">",
"      Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics 2001; 108:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/9\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/10\">",
"      Gopal AK, Whitehouse JD, Simel DL, Corey GR. Cranial computed tomography before lumbar puncture: a prospective clinical evaluation. Arch Intern Med 1999; 159:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/11\">",
"      Proulx N, Fr&eacute;chette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/12\">",
"      Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006; 34:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/13\">",
"      Lepur D, Barsi�� B. Community-acquired bacterial meningitis in adults: antibiotic timing in disease course and outcome. Infection 2007; 35:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/14\">",
"      Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001; 345:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/15\">",
"      Sinner SW, Tunkel AR. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am 2004; 18:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/16\">",
"      Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004; 39:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/17\">",
"      Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983; 71:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/18\">",
"      Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med 1981; 71:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/19\">",
"      Nau R, S&ouml;rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/20\">",
"      Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/21\">",
"      Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/22\">",
"      Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/23\">",
"      Lebel MH, Hoyt MJ, McCracken GH Jr. Comparative efficacy of ceftriaxone and cefuroxime for treatment of bacterial meningitis. J Pediatr 1989; 114:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/24\">",
"      Peltola H, Anttila M, Renkonen OV. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group. Lancet 1989; 1:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/25\">",
"      Cherubin CE, Appleman MD, Heseltine PN, et al. Epidemiological spectrum and current treatment of listeriosis. Rev Infect Dis 1991; 13:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/26\">",
"      Par&iacute;s MM, Ramilo O, McCracken GH Jr. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/27\">",
"      Cherubin CE, Eng RH, Norrby R, et al. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis 1989; 11:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/28\">",
"      van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006; 354:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/29\">",
"      Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994; 38:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/30\">",
"      S&aacute;ez-Llorens X, O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001; 20:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/31\">",
"      Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/32\">",
"      Clauss HE, Lorber B. Central nervous system infection with Listeria monocytogenes. Curr Infect Dis Rep 2008; 10:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/33\">",
"      Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/34\">",
"      Cottagnoud P, Acosta F, Cottagnoud M, T&auml;uber MG. Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002; 46:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/35\">",
"      S&aacute;ez-Llorens X, McCoig C, Feris JM, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/36\">",
"      Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/37\">",
"      van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/38\">",
"      Korinek AM, Baugnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2006; 59:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/39\">",
"      The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. Br J Neurosurg 2000; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/40\">",
"      Zarrouk V, Vassor I, Bert F, et al. Evaluation of the management of postoperative aseptic meningitis. Clin Infect Dis 2007; 44:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/41\">",
"      Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009; 9:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/42\">",
"      Oates-Whitehead RM, Maconochie I, Baumer H, Stewart ME. Fluid therapy for acute bacterial meningitis. Cochrane Database Syst Rev 2005; :CD004786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/43\">",
"      Kramer AH, Bleck TP. Neurocritical care of patients with central nervous system infections. Curr Infect Dis Rep 2007; 9:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/44\">",
"      Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis 2011; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/45\">",
"      Lindvall P, Ahlm C, Ericsson M, et al. Reducing intracranial pressure may increase survival among patients with bacterial meningitis. Clin Infect Dis 2004; 38:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/46\">",
"      Durack DT, Spanos A. End-of-treatment spinal tap in bacterial meningitis. Is it worthwhile? JAMA 1982; 248:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/47\">",
"      Ziai WC, Lewin JJ 3rd. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol 2009; 22:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/17/22810/abstract/48\">",
"      Kilpi T, Anttila M, Kallio MJ, Peltola H. Length of prediagnostic history related to the course and sequelae of childhood bacterial meningitis. Pediatr Infect Dis J 1993; 12:184.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1290 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22810=[""].join("\n");
var outline_f22_17_22810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENERAL PRINCIPLES OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Avoidance of delay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Effects of delay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Causes of delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotic regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bactericidal drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Drug entry into CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Route of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H168234278\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adjunctive dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Causative organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Empiric regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - No known immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Impaired cellular immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Healthcare-associated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Beta-lactam allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Empiric treatment during epidemics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      REGIMENS BASED UPON GRAM STAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      THERAPY FOR SPECIFIC PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Reduction of intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      REPEAT CSF ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Neurologic complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Prediction of risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Empiric antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - No known immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Impaired cell-mediated immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Healthcare-associated meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Allergy to beta-lactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1290|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/41/11935\" title=\"algorithm 1\">",
"      Initial mgmt bact mening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1290|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/55/14204\" title=\"table 1\">",
"      CSF analysis in CNS infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/37/12893\" title=\"table 2A\">",
"      Empiric abx purulent mening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/45/18141\" title=\"table 2B\">",
"      Bacterial meningitis adult antibiotic dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/57/11164\" title=\"table 2C\">",
"      Abx for meningitis based on Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/55/12158\" title=\"table 2D\">",
"      Meningitis treatment based on susceptibility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=related_link\">",
"      Epidemiology of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=related_link\">",
"      Neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38549?source=related_link\">",
"      Pathogenesis and pathophysiology of bacterial meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_17_22811="Options for emergency contraception";
var content_f22_17_22811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Options for emergency contraception",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reported efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levonorgestrel",
"       </td>",
"       <td>",
"        0.75 mg given twice, 12 hours apart",
"        <strong>",
"         or",
"        </strong>",
"        1.5 mg given as a single dose",
"       </td>",
"       <td>",
"        59 to 94&nbsp;percent of pregnancies prevented",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogen plus progesterone (Yuzpe regimen)",
"       </td>",
"       <td>",
"        100 to 120&nbsp;micrograms ethinyl estradiol plus&nbsp;500 to 600 micrograms&nbsp;levonorgestrel in each dose, given twice, 12 hours apart",
"       </td>",
"       <td>",
"        47&nbsp;to 89 percent of pregnancies prevented",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mifepristone*",
"       </td>",
"       <td>",
"        Single 600 mg dose",
"       </td>",
"       <td>",
"        99 to 100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper intrauterine device",
"       </td>",
"       <td>",
"        Inserted within 120 hours after intercourse",
"       </td>",
"       <td>",
"        at least 99 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulipristal",
"       </td>",
"       <td>",
"        Single oral dose of 30 mg",
"       </td>",
"       <td>",
"        98 to 99&nbsp;percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     <p>",
"      *Not available for emergency contraception&nbsp;in the United States.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22811=[""].join("\n");
var outline_f22_17_22811=null;
var title_f22_17_22812="DDX PHPT lab result";
var content_f22_17_22812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of primary hyperparathyroidism, typical laboratory findings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Laboratory test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Intact PTH",
"       </td>",
"       <td class=\"subtitle2\">",
"        Serum calcium",
"       </td>",
"       <td class=\"subtitle2\">",
"        Urinary calcium (mg/24 hours)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Ca/Cr clearance",
"       </td>",
"       <td class=\"subtitle2\">",
"        25OHD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PHPT",
"       </td>",
"       <td>",
"        High-normal or elevated",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Normal or elevated",
"       </td>",
"       <td>",
"        0.01 to 0.05 (&gt;0.02)",
"       </td>",
"       <td>",
"        Normal or low-normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        Low (&lt;20 pg/mL)",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Depends on malignancy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FHH",
"       </td>",
"       <td>",
"        Normal, mildly elevated in 15 to 20 percent",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Low (&lt;100)",
"       </td>",
"       <td>",
"        &lt;0.01",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PHPT with vitamin D deficiency",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Normal or elevated",
"       </td>",
"       <td>",
"        Low-normal or low (&lt;200)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Low (&lt;20 ng/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normocalcemic&nbsp;PHPT",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary&nbsp;hyperparathyroidism due to vitamin D deficiency",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Normal or low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Low (&lt;20 ng/mL)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PHPT: primary hyperparathyroidism; FHH: familial hypocalciuric hypercalcemia; 250HD: 25hydroxyvitamin D; Ca/Cr: calcium/creatinine.",
"     <br>",
"      * 25-hydroxyvitamin D is often normal in malignancy. It could be low in cases of concomitant vitamin D deficiency, due to poor dietary intake and little sun exposure. The 1,25-dihydroxyvitamin D may be elevated, depending upon the malignancy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22812=[""].join("\n");
var outline_f22_17_22812=null;
var title_f22_17_22813="Burn mortality in MIC";
var content_f22_17_22813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Estimated global mortality rates from fire-related burn injuries in 2004: Middle income countries.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 328px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mortality rates are expressed as deaths per 100,000 population. In middle income countries (MIC) the mortality rate is highest in the age group 60 years and older. Mortality rates are higher for males age 15 years and older, while the mortality rate is higher for females in the 0-14 year age group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva 2008. Available online at: www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.(Accessed on April 2, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22813=[""].join("\n");
var outline_f22_17_22813=null;
var title_f22_17_22814="Contents: Anxiety disorders";
var content_f22_17_22814=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Anxiety disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Anxiety disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/32/11782\">",
"           Acute procedure anxiety in adults: Course, screening, assessment, and differential diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/39/9849\">",
"           Acute procedure anxiety in adults: Epidemiology and clinical presentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7080\">",
"           Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10488\">",
"           Agoraphobia in adults: Epidemiology, clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/42/24232\">",
"           Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38553\">",
"           Comorbid anxiety and depression: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41177\">",
"           Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30678\">",
"           Deep brain stimulation for treatment of obsessive-compulsive disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/0/32776\">",
"           Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36564\">",
"           Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42582\">",
"           Obsessive-compulsive disorder in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/42/44713\">",
"           Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2665\">",
"           Pharmacotherapy for generalized anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/0/23561\">",
"           Pharmacotherapy for obsessive-compulsive disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/8/7305\">",
"           Pharmacotherapy for panic disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33239\">",
"           Pharmacotherapy for posttraumatic stress disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/49/27416\">",
"           Pharmacotherapy for social anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/41/6806\">",
"           Pharmacotherapy for specific phobia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27352\">",
"           Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20505\">",
"           Psychotherapy for generalized anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/37/34391\">",
"           Psychotherapy for obsessive-compulsive disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/22/40297\">",
"           Psychotherapy for panic disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/58/5032\">",
"           Psychotherapy for posttraumatic stress disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32327\">",
"           Psychotherapy for social anxiety disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/59/25527\">",
"           Psychotherapy for specific phobia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/44/44744\">",
"           Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/24/22921\">",
"           Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/0/26632\">",
"           Treatment for specific phobias of medical and dental procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9512\">",
"           Treatment of acute procedure anxiety in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24197\">",
"           Treatment of acute stress disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29993\">",
"           Treatment of co-occurring anxiety disorders and substance use disorders",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-318A11D150-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_17_22814=[""].join("\n");
var outline_f22_17_22814=null;
var title_f22_17_22815="Low grade cystic duct leak";
var content_f22_17_22815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Low grade cystic duct stump leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP shows extravasation from the cystic duct stump. It was necessary to fill the intrahepatic biliary tree to demonstrate the leak.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_17_22815=[""].join("\n");
var outline_f22_17_22815=null;
